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Resumo
O aumento da prevalência mundial da obesidade é um grave problema de saúde pública.Entre as muitas complicações associadas à obesidade, estão algumas patologias malig-nas. O melanoma é um dos cancros cuja incidência apresenta mais rápido crescimento
e a obesidade tem sido apontada como um possível fator subjacente à maior prevalência de mela-
noma. No presente trabalho, abordou-se esta relação e investigaram-se os mecanismos biológicos
que relacionam a elevada adiposidade com a progressão do melanoma. Recorrendo a culturas ce-
lulares de melanócitos malignos de murganho (B16-F10) e humanos (MeWo) tratados com meio
condicionado (MC) de adipócitos 3T3-L1 e de fragmentos ex vivo de tecido adiposo subcutâneo
(TAS) e visceral (TAV), demonstrou-se que a gordura liberta fatores potenciadores da proliferação,
atividade metabólica e simultaneamente inibidores da apoptose das células de melanoma. A migra-
ção e adesão celulares foram distintamente moduladas pelos MC do TAS e TAV. Além disso, o MC
dos adipócitos 3T3-L1 promoveu a sobrevivência e homeostasia redox das células B16-F10 após tra-
tamentos de radioterapia. O aumento da viabilidade, motilidade e defesas antioxidantes dos mela-
nócitos, com uma ativação concomitante da via de sinalização da AKT, reverteu os danos induzidos
pela radiação ionizante contribuindo para a radiorresistência dos melanócitos. Subsequentemente,
murganhos C57Bl/6J alimentados com uma dieta rica em gordura foram inoculados com células de
melanoma B16-F10 por via subcutânea ou intravenosa. In vivo, a adiposidade potenciou a progres-
são e a vascularização domelanoma primáriomas, por outro lado, diminuiu o potencialmetastizante
das células B16-F10 em circulação. Curiosamente, em culturas 3D in vitro, os fatores libertados pe-
los adipócitos induziram a reorganização das células B16-F10 e MeWo em estruturas tipo-capilar
caraterísticas de mimetização vascular (MV). Observou-se também um aumento in vivo daMV nos
animais HFD, apesar de estatisticamente não significativo. A caraterização molecular do soro dos
animais, bem como do MC das células 3T3-L1 e do TAS e TAV, permitiu destacar possíveis media-
dores moleculares e mecanismos biológicos pelos quais o tecido adiposo promove a vascularização
e a progressão do melanoma. Em suma, estes resultados reforçam os efeitos nefastos que um mi-
croambiente rico em fatores derivados do tecido adiposo induz na progressão, agressividade, stresse
oxidativo, angiogénese e MV tumoral, com possíveis implicações diretas no prognóstico, resposta
ao tratamento e, em última análise, sobrevida dos pacientes commelanoma.
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Abstract
O besity is now a major health problem due to its rapidly increasing incidence worldwide.Among many conditions associated with obesity are some malignancies. The incidenceof melanoma has been increasing steadily over the past decades and obesity has been
pointed out as a potential underlying morbidity subsidising melanoma development. In the present
work, we address the above relationship and inquire into the biological mechanisms linking high-
adiposity and melanoma progression. Employing murine B16-F10 and human MeWo melanoma
cell cultures exposed to 3T3-L1 adipocytes secretome, and ex vivo subcutaneous (SAT) and visceral
(VAT) adipose tissue conditioned medium (CM), we were able to demonstrate that fat-released
factors heighten melanoma cell proliferation, metabolic activity, and simultaneously decrease apop-
tosis. B16-F10 cell migration and adhesive properties were distinctively modulated by SAT and
VAT released factors. Furthermore, 3T3-L1 adipocytes CM upheld B16-F10 cell survival and redox
homeostasis following radiotherapy treatments. Remarkably, 3T3-L1 secretome increased melano-
cytes viability,motility, catalase activity and total antioxidant status, with a concomitant activationof
the AKT signalling pathway, reversing ionizing radiation damages and enhancing the radioresistant
phenotype of melanocytes. Subsequently, we employed a high-fat diet (HFD)-induced obese mice
melanoma allograftmodel, where C57Bl/6Jmice were subcutaneously or intravenously) inoculated
with B16-F10melanoma cells. In vivo fat-released circulating factors led to subcutaneousmelanoma
growth and vascularization but, on the other hand weakened the metastasizing capacity of circulat-
ing malignant B16-F10 cells. Surprisingly, exposure to 3T3-L1 CM induced B16-F10 and MeWo
cells to rearrange, on 3D in vitro cultures, into characteristic vasculogenic mimicry (VM) vessel-like
structures. An in vivo increase in VM was also observed in tumour-bearing HFD animals, though
not reaching statistical significance. Our findings are corroborated by molecular characterization
of animals serum, as well as 3T3-L1, SAT, and VAT CM, and led us to highlight possible molecular
candidates andmechanisms bywhich adipose tissue promotesmelanoma progression and enhances
vascularization. Altogether, our results reinforce the deleterious effects that an adipose-derived fac-
tor-rich environment partakes inmelanoma progression, aggressiveness, oxidative stress, angiogene-
sis and VMwith direct implications in disease prognosis, treatment outcomes and ultimately overall
survival.
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Introduction
C ancer is a worldwide phenomenon. Its relation with obesity has become a reality in ourdays. The common features of the two most deadly and chronic diseases of the modernworld overlap in many characteristics along their pathogenesis. In this review the current
scientific and medical state of the art of both diseases are explored, enlightening their cross-talk and
putative overlapping role in melanoma.
1.1 Melanoma
Melanoma, also known as malignant melanoma, is a cancer that develops in melanocytes. Mel-
anoma predominantly occurs in the skin, but may in rare instances occur at other sites, and pos-
sesses an high metastasis potential and poor survival rates once metastasised. Melanoma is one of
the world’s most rapidly increasing malignancies. (1) Cutaneous melanoma prevalence has been in-
creasing year by year in the last decades, (2)with an estimatedoublingof incidence rates every 10 to20
years, (3,4) raising melanoma to the most rapidly increasing cancer in Caucasians. (4) Annually more
than 176000 new cases ofmelanoma are found solely in Europe and theUS. (5,6) Althoughmalignant
melanoma comprises less than 10% of diagnosed dermatologic cancers, it is responsible for almost
80% of skin cancer deaths. Globally, in 2012, melanoma occurred in more than 200000 people and
resulted in 55000 deaths. (7)
The causes of melanoma development are multifactorial and not fully elucidated. However, sev-
eral risk factors are known to contribute tomelanoma development: intermittent sun andUV-radia-
tion exposure, a previous episode or family history of melanoma, high number of nevi present in the
skin, the degree of skin pigmentation, a weakened or suppressed immune system, among others. (2,8)
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Standard approaches in melanoma treatment involve surgical resection when diagnosed at early
stage, chemotherapy and radiation therapy (RT) together with immunotherapy in the later stages
of the disease. However, these approaches are less effective in terms of advanced and metastatic
melanoma.
1.1.1 Histologic Changes inMelanoma Progression
In the skin, maintenance of tissue homeostasis determines whether a cell remains quiescent, pro-
liferates, differentiates, or undergoes programmed death. Melanocytes are found in the deepest layer
(the stratum basale) of the skin’s epidermis and, upon proliferation, migrate along the basal layer ex-
tending their dendrites to establish contacts with adjacent keratinocytes and Langerhans cells. (9)
Under normal conditions, surrounding keratinocytes control the growth and behaviour of melano-
cytes by means of a complex system of mechanic cell-to-cell adhesive interactions and the secretion
of paracrine growth factors. (10,11) Once this delicate homeostatic balance is disrupted, melanocyte
proliferation andmigration becomes unrestrained, which can result in the formation of nevi or even
malignant melanoma development. (10)
Thegreat majority of melanomas begin as intraepidermal proliferations, whichmay have some re-
lationship to a melanocytic nevus. The histological diagnosis of melanocytic lesions requires assess-
ment of architectural and cytological features that are more often present in melanoma than benign
nevi, such as higher lesional diameter, asymmetry and architectural disorder, pagetoid melanocyto-
sis, poorly circumscribed lesions, nesting and sheetlike arrangements of melanocytes, high degree
of cytological atypia, nuclear atypia and enlarged nuclei with irregular contours, effacement of the
epidermis, absence of maturation, dermal mitoses, ulceration, and host immune response. (12) His-
tological interpretation discloses three clinically and histomorphologically distinct steps alongmela-
noma progression. In an early stage, the tumour may be confined to the epidermis and displays only
radial/lateral growth (melanoma in situ). When melanoma progresses, it can develop into microin-
vasive melanoma, in which microscopic extensions invade the uppermost layers of the dermis. As
melanomas further advance, they progress to the vertical growth phase, which is characterized by in-
vasive growth with discernable involvement deep into the dermis and subcutaneous fat layer. In this
stage of growth, the melanoma has entered the tumourigenic and/or mitogenic phase and gained
the potential to metastasise. (13)
Along melanocytes progression to malignancy, alterations in gene expression patterns include
genes that are usually expressed by several other cell types such as precursors of endothelial, per-
icyte, fibroblast, haematopoietic, kidney, neuronal and muscle cells. (14,15) Aggressive melanoma
cells can “mask” as other cell types while reverting to a more embryonic-like undifferentiated phe-
notype, (16) through an epithelial-to-mesenchymal transition-like reprogramming. (17) In addition to
the tumourigenic genetic abnormalities, it has been shown that interactions betweenmelanoma cells
and surrounding stromal environment are significant. Melanoma cells are embedded in a cell-rich
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tissuemicroenvironment and surrounded bymultiple cell types including keratinocytes, fibroblasts,
endothelial cells and immunoregulatory cells. In malignant melanoma, tumour-stroma interactions
involve several biological mechanisms, including changes in intercellular and cell-matrix adhesions,
up-regulation of autocrine/paracrine growth factors and their receptors and stimulation of angio-
genesis and immune cell response that cooperate in a concerted action to rise up the growth and
invasion of malignant melanoma cells. (18)
Melanoma can arise as a pigmented lesion or less frequently, as non-pigmented or amelanotic
lesions (2% of melanomas). (19) Melanocytes are cells specialized in the synthesis of melanin pig-
ments. Although the main function of melanin is to protect against UV-induced damage, synthesis
and accumulation of abnormal melanin pigment and dysfunctional or fragmented melanossomes,
usually altered in pigmented melanoma lesions, (20) is generally associated with aggressiveness, ox-
idative stress, and resistance to treatment. (21–23) However, and in spite of significant research efforts,
the relationship between melanin content and metastatic phenotype and prognosis of melanoma
still remains controversial.
Along melanoma progression, tumours acquire and sustain a dense vascular network, enabling
their adhesion to the vascular bed, favouring tumour cells extravasation and metastasis. (18) Mela-
noma neovascularization has been correlated with ulceration, poor overall survival and increased
rate of relapse. (24) The degree of tumour vascularity is one of the most important histopathologic
factors determiningoverall survival. Besides angiogenesis, vasculogenicmimicryprovides an alterna-
tive, angiogenic-independent tumour microcirculation. (16,25,26) It is well established that melanoma
cell-lined vascular networks sustain a redundant blood supply, with a viable blood flow between
tumour-cell-lined vascular spaces and endothelium-lined and/or mature vasculature, required for
both growth and metastasis. (25,26) The presence of these functional vascular mimetic channels by
the tumour itself stands a predictor of poor prognosis in human melanoma patients (27,28), but little
is known about the biological relevance of this phenomenon.
1.1.2 Molecular Basis ofMelanoma Pathogenesis
Melanoma etiopathogenesis is heterogeneous; it partly depends on genomic mutations, which
lead to the activation of proto-oncogenes or to the inactivation of suppressor genes as well as the
amplification/deletion and translocation of parts orwhole chromosomes. None of the oncogenes or
tumour suppressor genes identified inmelanoma is thought to be deregulated in stand-alone events,
even though some of the critical mutations in melanoma cells are mutually exclusive.
Several altered intracellular signaling pathways have been identified in melanomas so far, the best
known of which is the mitogen activated protein kinase (MAPK) pathway orRAS-RAF-MEK-ERK
pathway (Fig. 1.1). (29)The intracellularMAPK pathway can be activated by various extracellular sig-
nals. Growth factors such as epidermal growth factor (EGF), insulin-like growth factor (IGF)-I, or
transforming growth factor (TGF)-ß induce signal transduction by binding to the respective recep-
3
introduction chapter 1
P
F F
P
MEK MEK
P
ERK ERK
SOSGRB2
PI3K
GTP
S
GDP
S
AKT
Growth Factors
Receptor
Tyrosine Kinase
PIP2PIP3
PI3K Pathway MAPK Pathway
NRAS
(2o%) 
*
BRAF
(50-60%) 
*
AKT3
(25%) 
*
PTEN
(30%) 
*PTEN
→Survival→Proliferation
←Apoptosis
Figure 1.1: TheMAPK and PI3K-AKT signalling pathways in melanoma. Diagram of key activators, regula-
tors and critical mutations of theMAPK and PI3K-AKT signaling cascades in malignant melanocytes.
tors located on the cell surface. This, in turn, leads to the activation of theRAS protein which trans-
ducts the signal to theRAF group of serine-threonine kinases, including ARAF, BRAF, and CRAF.
Each of those three kinases may activate MEK kinases. In turn, MEK kinases activate the following
stage of the pathway - ERK kinases, that either phosphorylate cytoplasmic proteins or migrate into
the cell nucleus influencing the transcription factors regulating genes connected with proliferation,
differentiation and apoptosis. (30)
It has been estimated that about 50-60% of melanomas contain MAPK pathway activating muta-
tions, rendering this pathway as the most important therapeutic target. (29) NRAS harbours activat-
ing mutations in 15–20% of melanomas. Several somatic mutations in the BRAF gene have been
described so far. The most commonly observed mutation in melanomas is BRAF-V600E, which
ranges in frequency from 30% to 72%. (31) As BRAFmutations conferRAS-independent activation
of theMAPK pathway, concomitant BRAF and NRASmutants are rarely found. (32)
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Melanomas also harbour abnormalities in the PI3K/AKT signalling pathway, but they are ob-
served at lower frequencies. The PI3K-AKT pathway is activated by a number of different factors,
including ligands binding to tyrosine kinases receptor and G protein-coupled receptors and GTP
binding ofRAS proteins. These signals activate the catalytic activity of PI3K, which phosphorylates
inositol molecules found on phospholipids in the plasma membrane, resulting in the generation of
phosphatidylinositol-(3,4,5)-P3 (PIP3). PIP3 activates downstream signaling effectors, the most
notable one being the serine-threonine protein kinases AKT1, AKT2, and AKT3, which activate
downstream anabolic signaling pathways required for cell growth and survival. Protein phosphatase
PTENdephosphorylatesPIP3 tophosphatidylinositol-(4,5)-P2 (PIP2) anddirectly antagonizes the
activity of PI3K kinase. (33)
ThePI3K-AKTpathwayhas been shown to complement activationof theMAPKpathway inmela-
nocyte transformation. Mutations involvingPI3K itself are rare inmelanoma. However, significantly
increased expression of p-AKT was observed in melanomas with complete loss of PTEN. Deleteri-
ous mutation or loss of PTEN have been described in 10% to 30% of melanomas. These events also
seem to coincide with BRAFmutation and are mutually exclusive with NRASmutations. (34–36) Al-
terations of AKT1 and AKT2 genes are rare, but genetic gain of AKT3 is seen in 25% of melanoma
tumours. (37,38)
Less common genetic alterations, such as cyclin D1 amplification and cyclin-dependent kinase 4
mutation have also been identified in association with BRAFmutation. Other genomic aberrations,
such as amplification ofmicrophthalmia-associated transcription factor, loss of expression of the p16
also represent oncogenic events in melanomas. (36,39) Still, 30–40% of melanomas do not bear iden-
tifiable driver mutations by conventional clinical assays and are considered to be ‘pan-negative’. (40)
The lack of clearly detectable mutations or available targeted therapies makes this a challenging co-
hort in the clinic.
Nevertheless, melanoma still remains a paradox among all solid tumours. Despite the fact that
many critical mutations and prognostic markers have already been identified, there is very little un-
derstanding of their biological role and interplay in the transformation of melanocytes into mela-
noma cells, as well as their contribution to the metastatic phenotype. In fact, the prognosis of malig-
nant melanoma relies mainly on histological criteria such as tumour size, thickness, ulceration and
mitotic activity. However, the identification of novel critical driving mutations and signalling path-
ways represents potential new therapeutic targets for human melanoma treatment.
1.1.3 Management ofMelanoma
Malignant melanoma is among the most notoriously aggressive and treatment-resistant human
cancers. Melanoma therapy remained the same for several decades: surgical excision of the malig-
nant mass remains the mainstay of primary melanoma treatment at all sites. An early diagnosis fol-
lowed by the appropriate surgical technique is currently the only demonstrated effective treatment.
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In theory, surgery allows locoregional disease control without severe functional and/or aesthetical
impairments. (41) However, the prognosis for melanoma patients with distant metastases is generally
poor, with historical 5-year survival rates of less than 10%. (42)
1.1.3.1 Chemotherapy, Targeted Therapy and Immunotherapy
Cytotoxic chemotherapy has been used for the treatment of advanced melanoma for over 4
decades. Dacarbazine still is the chemotherapeutic agent of choice in metastatic melanoma. Temo-
zolomide, another alquilating agent, is preferredwhencentral nervous systemmetastases arepresent. (43)
However, the overall success of chemotherapy in metastatic melanoma is quite limited. Metasta-
tic melanoma has historically carried an especially poor prognosis, with an average survival of 6-9
months. (42,43) In recent years, however, major breakthroughs in both immune-based therapies and
molecularly targeted inhibitors brought great advancements and expanded the treatment options for
patients with this disease. (44)
One the most important milestones was the approval of immune-checkpoint inhibitors that tar-
get the mechanisms of tumour immunosuppression, including cytotoxic T lymphocyte-associated
antigen (CTLA)-4 and programmed death (PD)-1 receptors. CTLA-4 and PD-1 are immune check-
point receptors expressed by T-cells that upon binding to its ligands, which are expressed on mela-
noma cells, negatively regulateT-cell activation thereby causing immunosuppression andpreventing
the immune system from triggering an immune T-cell response to the tumour. (45) Ipilimumab, an
inhibitor of CTLA-4, and nivolumab and pembrolizumab, both PD-1 inhibitors, are monoclonal
antibodies approved as immunotherapies for melanoma that target these receptors resulting in in-
creased activation of inflammatory tumour-cell removal responses. (36,45)
The discovery of many critical mutations in melanoma led to the introduction of targeted molec-
ular inhibitors in melanoma therapy. BRAF protein inhibitors such as vemurafenib and dabrafenib
or MEK inhibitors cobimetinib and trametinib are approved drugs that combine the inhibition of
intracellular MAPK signal transduction. Inhibition of NRAS, ERK, AKT and other intermediaries
of the major altered signaling pathways identified in melanomas is an emerging therapeutic strategy
and represents another major leap in melanoma treatment. (36,44)
Moreover, there are many ongoing clinical trials testing the efficacy and safety of new molecules
and treatments. The results of various combinations of approved drugs, treatment modalities and
new promising agents keep emerging in the literature. Researchers continue working on new possi-
ble methods of treatment and combinations of adjuvant therapies as resistance to the immuno and
targeted therapy drugs is a commonly observed complication. (46)
1.1.3.2 Radiation Therapy
RT is frequently employed as a treatment option for the majority of malignancies. However
melanomas reputation as a prototypical RT-insensitive cancer still discourages the use of ionizing
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radiation as an adjuvant therapy in melanoma patients. Wide local surgical resection has proved ef-
fective at low risk for primary melanoma lesions, so RT is not a first-line treatment. (41) Radiation
therapy (whole-brain irradiation and/or stereotactic radiosurgery) is particularly useful in the man-
agement of brainmetastases, asmost systemic chemotherapeutic drugs have limitedpenetration into
the central nervous system or when adequate surgical margins cannot be guaranteed, such as with
melanoma lesions of the head and neck. (47)
The role of adjuvant RT in melanoma therapy has generally been limited to palliative care be-
cause melanoma has historically acquired a biased reputation as a radioresistant tumour. (48) How-
ever, recent clinical trials combining appropriately fractionated higher delivered doses of radiation
with immunotherapy and chemotherapy agents improved the outcome of treatment and palliation
of symptomatic melanoma metastases, endorsing RT to play a greater role in melanoma manage-
ment. (44,49,50)
1.1.4 Final Remarks
Malignant melanoma is an aggressive and clinically complex malignancy. Melanoma can arise
from very distinct anatomic locations with numerous, and sometimes rare, subtypes. Distinguish-
ing ambiguous dysplastic nevi from those true melanoma represents a challenge in histopathologic
diagnosis. Most diagnostic biomarkers of melanoma rely on detection of melanocytes rather than
melanoma itself and currently there are no serologic markers for the early detection of melanoma.
Melanoma etiology results from an intricate combination of environmental factors and genetic ab-
normalities. However, there is very little understanding of their biological role in disease progression.
Melanoma unique biology challenges clinical control of the disease and improvement in patient sur-
vival has been an arduous path. However, poor prognosis for patients withmetastatic melanoma has
changed radically over past few years. The medical approaches in practice are becoming more and
more promising as several novel agents designed for patients with advancedmelanoma appeared just
a few years ago. Numerous clinical studies present clinical benefit of treatment with new biological
agents and molecular inhibitors over standard chemotherapeutics, but melanoma management still
is a major challenge for clinicians. Participation in clinical trials remains a mainstay for patients with
melanoma. Nevertheless, patients diagnosed with melanoma today are given a chance to access so-
phisticated treatment that has never been available before.
1.2 Obesity andMelanoma
Adipose tissue (AT) has long been recognized as a mere reservoir of energy. When the caloric
intake surpassed the body daily needs, extra-energy is converted to high-caloric fatty acids, and later
stored in adipocytes. When extra energy is required, or over long periods of fasting, the fatty acids
stored in adipocytes are mobilized to provide energy for other tissues. With the “modern lifestyle”,
7
introduction chapter 1
obesity has become prevalent and novel functions for AT have been unveiled. Parallel to the fat-
storage specialization, adipocytes are secretory cells that produce a panoply of molecules, generally
named as adipokines. Adipokines mediate vast functions in our organisms, from appetite to inflam-
mation, including angiogenesis. Nowadays, the knowledge about AT is accumulating, changing our
view on adiposity and raising it to an inflammatory and endocrine organ. (51)
The excessive accumulation of fat and AT expansion are serious risk indicators for metabolic im-
pairment. Obesity is implicated in the development of metabolic syndrome, contributing to the on-
set of hypertension and dislipidemia, the development of atherosclerosis and cardiovascular compli-
cations, and the establishment of glucose intolerance, peripheral insulin resistance and the pathogen-
esis of type 2 Diabetes mellitus. (52–54) AT dysfunction, along the development of obesity, promotes
the instalment of a chronic low-grade inflammatory state inmetabolic tissues, that is accompanied by
a parallel increase in systemic oxidative stress. (55–58) However, the spaciotemporal interdependency
of these biological hallmarks in the pathogenesis of obesity has yet to become better understood.
In 2003, a new epidemiologic link between between obesity and several types of malignancies
raised the alarm in the scientific andmedical communities. (59) The risk of obesity-associated cancer
is nowwell establishedbymore than adecadeof scientific research. (60)Obesity is not only associated
with the onset of cancer, but has also a negative impact in the disease progression leading to a wors-
ened prognosis and a higher mortality risk from the most common forms of cancer in overweight
patients. (61,62)
Not all cancers are associatedwith obesity and the relative risk varies amongdifferent cancer types.
In epidemiologic studies, obesity-associated cancer risk is often quantified as the ratio of the proba-
bility change in risk per 5 kg/m 2 increase in bodymass index, a measure of adiposity. Using this for-
mula, recent meta-analysis estimate a malignant melanoma relative risk in between 1.17-1.31, (63–65)
however other prospective cohort studies showed no significant association between obesity and
risk for malignant melanoma. (62,66)
1.2.1 Mechanisms LinkingObesity andMelanoma
ATexpansion, during the development of obesity, shares several biological similarities withmalig-
nant neoplasms. Both tissues exhibit considerable and rapid expansion and cause deleterious effects
on the organism. Any expanding tissue is challenged to vascularize the growing mass in order to
provide access to sufficient O2 and nutrients, overcoming hypoxia. Both diseases share significant
alterations in immune responses and adipose/cancer cells have the capacity to establish interactions
and modulate immune cells. Finally, dysfunctional adipocytes and neoplasic cells have abnormal
gene expression profiles and factor secretion patterns, with similar modulation of parallel signaling/
metabolic pathways during adipogenesis and oncogenesis. (67,68)
Taking into account the overlapping characteristics of both pathologies, several molecular inter-
mediaries and biological processes have been investigated in an attempt to disclose the contribution
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of obesity to the initiation, development and progression of malignant melanoma. Adipose growth-
factors, hypoxia, angiogenesis, inflammation, oxidative stress and energeticmetabolismhave all been
postulated as possible biological candidates in the cross-talk between fat deposition and the patho-
genesis of melanoma and will be reviewed in the following sections (Fig. 1.2). Yet, the rationale
behind obesity-associated melanocyte carcinogenesis is a problem that is far from being completely
understood.
1.2.1.1 Adipokines and Growth Factors
Nowadays, AT is considered an endocrine organ due to the production of multiple bioactive
molecules. These adipose-derived secreted factors can exert effects at both local and systemic lev-
els. The great majority of these factors are cytokines, chemokines and inflammatory mediators, but
a role in growth regulation as a new aspect of adipokines has been revealed by novel adipocyte-re-
leasedmolecules. (69)Deregulatedproduction and/or secretionof these adipokines, causedby excess
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Figure 1.2: Mechanisms linking obesity and melanoma. Adipose growth-factors, hypoxia, angiogenesis, in-
flammation, oxidative stress and energy metabolism have all been postulated as possible players in the cross-
talk between fat deposition and the pathogenesis of melanoma.
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adiposity andATdysfunction, has been linked to the pathogenesis of various obesity-linked diseases,
including cancer. (62,70)
A number of biological changes associated with obesity have been identified as predictors of a
poor prognosis inmelanoma, including hyperinsulinemia, insulin resistance (71,72) and IGF-I activity,
changes in the production of adipokines, including increased circulating leptin (73,74) and resistin (74)
and decreased serum levels of adiponectin. (71,75) Although not expressed by melanocytes, IGF-I
and insulin are essential mitogens for normal and malignant melanocytes involved in the prolifer-
ation and strong evasion of apoptosis. (76) Leptin and resistin serve as angiogenic/mitogenic factors
in melanoma tumour growth and metastasis, (73,74,77,78) while adiponectin exerts primordially anti-
proliferative and anti-inflammatory effects. (72,79) In fact, the increased circulating levels of insulin
and leptin as well as the IGF-I signalling axis have already been proposed as a molecular link that
might aggravate melanoma carcinogenesis in obese individuals. (80)
Additionally, endocrine-mediated consequences of obesity also renders an increase in serum lev-
els of adipose-secreted growth factors. Elevated circulating levels of EGF,TGF-β, hepatocyte growth
factor (HGF), fibroblast growth factor (FGF)-1, FGF-2 and FGF-21, platelet-derived growth factor
(PDGF) have been reported in obese individuals. Interestingly, melanoma cells are very sensitive
to FGF-2 and EGF signaling. (81) Moreover, HGF is expressed inmostmelanomas and activates vari-
ous cellular signaling pathways involved in proliferation, migration, and invasion in a paracrine man-
ner. (16) HGF, IGF-I, EGF, FGFs and TGF-β are involved in phenotype switching in melanoma and
epithelial-to-mesenchymal-like transition, (82) while PDGF, HGF, TGF-β and EGF act as angiogen-
esis promotors as well. (83–85)
Adipose-derived secreted factors accumulation can induce signal transduction upon binding to
the respective receptors located on the surface of the melanoma cell. Overexpression of numerous
G-protein-coupled receptors and receptor tyrosine kinases has long been recognized to play cen-
tral roles in the metastatic melanoma phenotype. (86,87) This in turn leads to the activation of their
downstream signalling cascades, most of them converging at the PI3K/AKT and MAPK pathways.
However, mostmelanomas already harbour constitutively activatingmutations inMAPK andPI3K/
AKT pathways and raise doubts about the magnitude of the effects of these adipose-derived factors
in promoting melanoma carcinogenesis. Conversely, overexpression of some of these growth fac-
tors, by malignant melanocytes, promotes adaptive resistance to targeted therapies in melanoma (88)
and pharmacological receptor-inhibition, even though located upstream in the signaling cascade, re-
vealed some sort of effectiveness in reducing tumour growth in human melanoma. (89)
In fact, obesity-associated superfluousATcould be an important additional source of extracellular
mitogenic factors that provideparacrine stimulation andactivationof intracellular pathways involved
in proliferation, migration, and invasion of melanoma cells.
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1.2.1.2 Angiogenesis
With few exceptions, the majority of tissues in adult life are in a quiescent state. Their capacity to
expand is limited and, in non-pathological conditions, they remain in a homeostatic growth steady-
state. Unlike most other tissues, AT exhibits high plasticity in adulthood, with permanent growth
potential and almost unlimited expansion. AT humongous expansion potential allows it to account
for 40% of total body mass and expand or shrink up to 10 times its mass. Concomitantly with AT
expansion or reduction, the growth, maintenance and remodeling of a supporting network of vessels
must occur. Therefore, adipocytes must be capable of tightly regulating the angiogenic process.
In fact, decades ago surgeons have already realized that AT can improve wound healing by stim-
ulating angiogenesis. (90) This vascular growth-stimulating effect has been initially attributed to the
ability of adipocytes to produce vascular endothelial growth factor (VEGF). Nowadays, more and
more adipokines are known to have direct and indirect effects onAT vascularization. Adipocytes are
able to stimulate and/or inhibit angiogenesis, thus controlling and fine-tuning vascular remodeling.
AT secretes numerous angiogenic modulators including leptin, VEGF, FGF-2, HGF, tumour
necrosis factor (TNF)-α, TNF-β, interleukin (IL)-1β, IL-6, IL-8, placental growth factor (PlGF),
PDGF, visfatin, resistin, neuropeptide Y, leptin and angiopoietins, as well as antiangiogenic fac-
tors thrombospondin-1, plasminogen activator inhibitor (PAI)-1 or adiponectin, whose expres-
sion balance will determine the triggering or halting of the angiogenic switch. (91–94) In addition to
adipocytes, AT contains diverse cell types including adipose stromal cells (ASC) and adipose tis-
sue macrophages (ATM) that also contribute to angiogenesis. ASC also produce a pleiade of an-
giogenic factors (VEGF, HGF, GM-CSF, FGF-2, and TGF), (95,96) while macrophages also produce
VEGF and the angiogenic cytokines TNF-α, FGF-2, IL-1β, IL-6, and IL-8. (97) AT also produces
several matrix metalloproteinase (MMP)s including MMP-2 and -9, (96) which could potentially af-
fect preadipocyte differentiation andmicrovessel maturation bymodulating the extracellular matrix.
Moreover, MMPs release the matrix-bound VEGF and indirectly induce angiogenesis.
Angiogenesis is a pivotal process in neoplasic progression and metastasis. The de-novo forma-
tion of blood vessels is typically perceived as the tumour’s response to the low O2 pressures or hy-
poxic conditions. Several pro-angiogenic factors were discovered, which play a pivotal role in tu-
mour angiogenesis, including melanomas. Among these are VEGF, FGF-2, EGF and IL-8 as well
as PlGF, and PDGF. (83,84) However, hypoxia-independent drivers of melanoma angiogenesis have
also been described. (98) Hypoxia-independent expression of VEGF, IL-8 and FGF-2 may in fact be
more important thanhypoxia-inducedupregulationof these factors in the angiogenesis ofmelanoma
xenografts. (99).
Triggeringpro-angiogenic events evenbefore a critical tumourmass is reached, in anhypoxia-inde-
pendent manner, allows small tumour cell colonies to recruit blood vessels, providing the first entry
point into the vasculature, which produces the appropriate signals to metastasise. Adipose-derived
angiogenic factorsmight be a source of these premature angiogenic stimuli. The induction of an early
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switch to the vascular phenotype contributes to the acceleration of tumour growth, accompanied by
a deleterious impact in the disease metastatic onset in overweight individuals.
1.2.1.3 Hypoxia
The labile expansion of fatmass combinedwith the large hypertrophic adipocytes is not accompa-
nied by a proper expansion of the capillary network, disrupting the oxygen supply to adipocytes. (100)
Hypoxia in AT of obese individuals has been proposed a causal role in triggering the inflammatory
response in AT, with the release of cytokines, chemokines, and angiogenic factors, that would serve
to increase blood flow and stimulate angiogenesis, as well as the associated systemic metabolic com-
plications. (100–104)
Cells under low-oxygenationmust express numerous genes to properly adapt. Hypoxia inducible
factor (HIF)s are a family of well characterized heterodimeric factors that establish the main hy-
poxia-responsive cellular sensors and molecular mediators. (105) HIF-1α has been found to be ele-
vated in AT hyperplasia and has a putative role in adipocyte differentiation and function. (103,106,107)
Adipocytes exhibit extensive functional changes in culture in response tohypoxia andHIF-1α, which
alters the expression of up to 1,300 genes. These include genes encoding key adipokines such as lep-
tin, IL-6, VEGF, andMMP-2 andMMP-9, which are upregulated, and adiponectin, which is down-
regulated. (106,108)Hypoxia also inhibits the expression of genes linked to oxidativemetabolismwhile
stimulating the expression of genes associated with glycolysis. (108)
HIFs are key regulators of the vasculature homeostasis. (109) HIF-1α is a very powerful pro-an-
giogenic stimulator, with recognized roles in numerous hypervascularization disorders and cancer
neovascularization. In fact, activation of HIF-1α is upregulated by hyperinsulinemia and adipogen-
esis, but not by hypoxia in adipocytes, (110) suggesting that AT angiogenesis and VEGF expression
is neither HIF-1α nor hypoxia dependent. (110,111) Human AT samples from obese patients have, in
fact, pronounced greater levels of VEGF-A and other pro-angiogenic factors, (112,113) but there is no
significant increase in the number of capillaries formed and no organized vascular response to the
increased stabilization of HIF-1α has been observed. (114)
Studies from Bedogni et al. have previously demonstrated the importance of hypoxia of the skin
in melanocyte transformation and the development of melanoma. (115) Oncogenes such asRAS can
increase the expression of both VEGF and FGF-2. This effect is likely due to increased stabiliza-
tion/activity ofHIF-1α, a transcription factor that plays an essential role in tumour angiogenesis and
tumour progression. (109) Specifically, the mild hypoxic microenvironment of the skin contributes
to melanocyte transformation, and hypoxia-mediated melanoma proliferation occurs via the PI3K/
AKT andMAPK kinase pathways. (116). Simultaneously, hypoxia promotes both melanoma growth
andmetastasis in additionwith the accumulation of IL-10-secretingM2-likemacrophages within tu-
mours. (117)Hypoxia also increases the heterogeneity ofmelanoma cell populations, indicating that a
subset of cells rests as a treatment-resistant pool that confers incomplete response to treatment. (118)
12
chapter 1 introduction
Hypoxia is able to induce vasculogenic mimicry channel formation and promote tumour invasion-
related protein expression, such as MMP-2 and MMP-9, in melanoma, strengthening the invasive
and metastatic potential. (119) Silencing of HIF-1α protein production induced the apoptosis of hy-
poxia-tolerant and hypoxia-resistant melanoma cells in vitro, (118,120) further reinforcing the putative
role of hypoxia in melanoma etiology.
Actually, AT hypoxia in human obesity has been challenged. Despite the lower oxygenation of
AT in obese patients, (121) the low oxygen demand by adipocytes (122,123) might undermine the ex-
pected hypoxic state of the fat mass. Unlike in the diet induced obesity mouse models, adiposity
gain, in humans, develops over long periods of time. The slower expansion of the adipose mass, al-
lied to an larger vascular remodeling timeframe, that allows partial vascularization of at least some
of the expanding fat depots, can also account to the observed discrepancies, weakening the theory
of hypoxia-triggered angiogenesis-dependent metabolic dysfunction of AT in obesity. Additionally,
BRAF/MEK/ERKsignaling (124) and thePI3Kpathway (125) are involved in anhypoxia-independent
regulation of HIF-1α in cancer. HIF-1α accumulation can also take place in presence of increased
levels of reactive oxygen species (ROS) and nuclear factor-κB (NF-κB) in melanoma, (126,127) both
being commonly deregulated in this cancer type.
Given the anatomical vicinity of melanocytes to subcutaneous fat, obesity-associated hypoxia
might render a great impact in exacerbating the hypoxic microenvironment of the skin, endorsing
melanoma development. Additionally, the aberrant hypoxia-induced adipocyte secretome includes
several factors known to play a role in tumour cell proliferation, apoptosis, migration, inflammation,
and aggressiveness thatmight paracrinally induce changes directly inmalignant cells or in the tumour
milieu.
1.2.1.4 Inflammation
Macrophages play a key role in inflammatory diseases. (128) Visceral adiposity low-grade chronic
inflammation andATMaccumulation are pivotal in the deleterious effects for the obesity-associated
metabolic syndrome and insulin resistance. (57,129) In fact, macrophages andother inflammatory cells
in the AT cellular content ranges from up to 10% in lean subjects, compared to nearly 40% in over-
weigh individuals. (129) The massive infiltration of macrophages into AT leads to chronic inflamma-
tion that not only modifies local metabolism, but also influences systemic energy.
Generally, ATM have been characterized into two sub-populations: M1 and M2 macrophages.
While theM1macrophages are associatedwithmore pro-inflammatory cytokines,M2macrophages
display an anti-inflammatory profile. (130) Inobesity, it has beenproposed that a phenotypic switch in-
ducing aM2 toM1polarizationof theATMoccurs and could account for themetabolic impairments
and chronic inflammation of AT. (131,132) In addition to their immunological function macrophages
also modulate tissue growth and angiogenesis through the production of growth factors and pro-an-
giogenic cytokines, respectively. This dual role of macrophages is well known in tumour angiogen-
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esis. (133) In tumours, M1 macrophages are associated with pro-inflammatory tumour-cell removal
responses,whereasM2macrophages exhibit tumour-promotingproperties including theproduction
of proteolytic enzymes, the suppression of anti-tumour immune responses and act as tumour-asso-
ciated angiogenic sponsors. (133,134)
Inmost advanced tumours, and in contrast toATMpool, tumour-associatedmacrophages (TAM)
havebeen reported tobepreferentially shifted towards anM2-like anti-inflammatoryphenotype. (135)
In malignant melanoma, TAM and their secreted mediators may be involved in all steps of inva-
sion and metastasis, correlating in most cases with poor outcomes. (136) On the contrary, the pres-
ence of tumour-infiltrating lymphocytes is regarded as the host immune anti-tumour response and
is associated with improved survival. (137) Additionally to TAM-released cytokines, IL-1, IL-6, IL-8,
and IL-10, TNF-α and TGF-β are also produced by melanoma cells to stimulate proliferation in au-
tocrine loops, (138,139)while paracrinally theymodulate themicroenvironment, viaM2-macrophages,
to the benefit of tumour growth and invasion. (117,140,141) IL-6, IL-10, TNF-α, and TGF-β also regu-
late anti-melanoma immune responses, further increasing the immunosuppressive environment in
the tumour stroma. (142)
Nevertheless, TAM and ATM produce an overlapping collection of cytokines, such as TNF-α,
IL-1, IL-6, IL-8, monocyte chemotactic protein (MCP)-1 and TGF-β. (97,143) The mutual obesity-
associated ATM and TAM-released inflammatory factors mentioned above are involved in the reg-
ulation of tumour growth, angiogenesis, invasion, and/or promotion of cancer metastasis, (143) and
may in fact be a linking rationale in the contributionofAT-inflamation toworsen tumourprogression
andmelanoma risk. Recent studies revealed that high-fat diet-induced obesity and peritumoural AT
increases tumour progression and angiogenesis in B16-F10 melanoma allografts, with concomitant
accumulation of M2-macrophages and IL-6 and IL-10 signalling, further reinforcing these assump-
tions. (144,145)
1.2.1.5 Oxidative Stress
Excessive cellular production of ROS such as superoxide anions, peroxides and hydroxyl radi-
cals, imbalances redox homeostasis with the depletion of antioxidant defences, culminating in ox-
idative stress. Oxidative stress, which has long been recognized as an adverse event for promoting
tumourigenesis and cancer progression, plays a fundamental role in melanocytes UV-induced pho-
tocarcinogenesis. (146,147) Exacerbated levels of ROS can irreversibly modify protein, lipid and DNA
molecules, and permanently or temporarily change their cellular behavior, leading to the accumula-
tion of somatic DNA mutations, proto-oncogenes activation and epigenetic alterations. (148) At the
same time, increased signaling via AKT,RAS/RAF/ERK and NF-κB pathways, constitutively acti-
vated signaling cascades in melanomas, stimulate endogenous ROS production, further enhancing
oxidative damages in melanoma cells. (127,149)
Besides their harmful effects, ROS and oxidative stress are key mediators in the regulation and
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homeostasis of several signal transduction pathways in normal and cancer cells. (150) ROS-mediated
PI3K/AKT activation, (151) and NF-κB (149) signaling promote cell proliferation and apoptosis sup-
pression. ROS and reactive nitrogen species (RNS) are also implicated in HIF-1α stabilization, (152)
the expression of VEGF and VEGF receptors, (152,153) angiogenesis (153,154) and vasculogenic mimi-
cry (155) in melanomas.
However, both malignant and non-malignant melanocytes bear higher basal levels of ROS com-
pared to keratinocytes and epidermal fibroblasts. Recently, melanin, melanogenesis and melanoma
aberrantmelanossomeshavebeen foundas another sourceofROS, (21)which seemscounter-intuitive
at first. Melanin acts as a scavenger of active oxygen species and is in general regarded as protective
pigment. (156) However, melanin pigment plays a double role in the etiology of melanoma acting as
a two-edged sword: protecting themelanocytes against UV radiation and oxidative stress, but at the
same timemelanossomes acceleratemelanoma progression and resistance to the effects of ROS-gen-
erating treatment therapies, specially RT, (22,23,157) renderingmelanomas ionizing radiation resistant.
In addition to endogenous melanoma ROS production, other cells in the tumour microenviron-
ment can generate various ROS and RNS. TAM are effective producers of ROS and RNS and fur-
ther contribute to a pro-oxidant environment. (140) ROS produced from inflamed peritumoural AT
and cancer-associated adipocytes also accelerate oxidative stress within tumour cells andmight con-
tribute to cancer progression in overweight patients. (144)
In fact, oxidative stress has been proposed as a mechanistic link between obesity and cancer. (64)
Central adiposity is characterized by a general increase in systemic oxidative stress, in part through
the inflammatory process but also by enhanced levels of reactive oxygen and nitrogen species. (56,70)
Obese patients also have impaired antioxidant defences (55) that further increase oxidative damage
to DNA, RNA, lipids and proteins in a process that enhances carcinogenesis.
1.2.1.6 EnergyMetabolism
The main metabolic function of AT is to store energy as triglycerides and provide fatty acids for
other tissues and organs. In fact, fatty acids are the main secretion product of adipocytes. Tumour
cells display progressive changes in metabolic activity that correlate with malignancy, including de
novo lipid biosynthesis and the development of lipogenic phenotype. (158) Still, the fatty acids stored
in fat tissue can be an important reservoir of energy to sustain the rapid tumour growth.
Recent studies show the transfer of lipids from adipocytes to melanoma cells. In melanoma cell
line B16-F10 adipocyte-released palmitic acid has a positive proliferative effect inmelanoma growth
and palmitic acid-pretreated B16-F10 cells resulted in larger tumours upon inoculation in mice. (159)
The fatty acid synthesis pathway is activated in various types of cancers and seems to be an impor-
tant mediator in the link between obesity and melanoma. (160) Both palmitic acid and fatty acid syn-
thase have an impact on the activation status of AKT with a concomitant stimulation of AKT sig-
naling cascade in a PTEN-independent way, although the underlying mechanisms are not fully elu-
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cidated. (159,160) In melanoma, reducing intracellular palmitic acid/fatty acid levels by lipase activ-
ity blockage (161) or by inhibiting fatty acid synthase (74,162) induces cancer apoptosis and reverses
obesity-induced rapid melanoma progression and metastasis.
These effects not only suggest the importanceof fat-stored lipids as fuel to tumour growth, but also
suggest that both exogenous and endogenous fatty acids are mediators in critical signaling pathways
in melanoma. Thus, melanoma tumourigenesis involves communication between tumour cells and
neighboring adipocytes, posing as another molecular link in the melanoma-obesity rationale.
1.2.2 Final Remarks
Obesity has long been recognized as a risk factor formetabolic impairment, contributing to hyper-
lipidemia, atherosclerosis, cardiovascular complications and type 2Diabetes mellitus. Last few years
brought a novel view on the possible deleterious contributions of high adiposity to cancer onset and
progression, including melanomas. Obesity and cancer have complex etiologies and pathophysio-
logical mechanisms. However, both morbidities exhibit undoubtedly too many similarities, from
molecular and cellular players to biological processes and signalling pathways, even similar microen-
vironments. Adipose growth-factors, adipokines, cytokines, hypoxia, angiogenesis, inflammation,
oxidative stress and energy metabolism are all possible candidates in the cross-talk between obesity
and cancer. In fact, obesity is a complex, multifactorial and multi-system disease and a “one mecha-
nism fits all” is unlikely to exist.
The obesity-carcinogenesis relation is not fully elucidated and still remains controversial for ma-
lignantmelanoma. Nevertheless, sufficient evidence exists to support ongoing and planned research
studies to further acquire in-depth knowledge and evidence to attain a more clear understanding of
this rationale.
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1.3 Rationale
The incidence of melanoma has been increasing steadily over the past few decades in most west-
ern countries and obesity has been postulated to be one of the causes for the increased incidence of
melanoma. However, literature on this subject is scarce, with limited and scant in-depth evidence
about the obesity-associatedmelanoma carcinogenesis. Indeed,many questions still need an answer
in the relationship betweenobesity andmelanoma. High adiposity is associatedwith a dysfunctional
secretion profile ofmultiple bioactivemolecules as well as with amore pro-oxidant status. Oxidative
stress, in turn, is a major player in radiotherapy. Herein, we aim to unravel the biological role of adi-
pose derived factors, focusing on fat-released adipokines, growth factors and angiogenicmodulators,
in our search formechanisms of obesity-enhancedmelanoma progression. Our research efforts were
divided in three separate and specificmilestones with inherent specific objectives defined as follows:
• evaluate the biological roles and direct paracrine effects of both adipocyte and adipose tissue
secretomes towards malignant melanocytes proliferation and plasticity in vitro;
• investigate the effects of fat-derived growth factors in melanoma cell survival, oxidative stress
and radioresistance employing an in vitro radiotherapy cell culture model;
• elucidate the in vivo effects of high-fat diet feeding in melanoma progression and metastasis,
focusing on tumour vascularization and vasculogenic mimicry;
17
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Effect of Adipocyte Secretome inMelanoma
Progression and VasculogenicMimicry
Coelho P, Almeida J, Prudêncio C, Fernandes R and Soares R
Journal of Cellular Biochemistry 2016; 117(7):1697–1706
ABSTRACT
Obesity, favored by the modern lifestyle, acquired epidemic proportions nowadays. Obesityhas been associated with various major causes of death and morbidity including malignantneoplasms. This increased prevalence has been accompanied by a worldwide increase in
cutaneous melanoma incidence rates during the last decades. Obesity involvement in melanoma ae-
tiology has been recognized, but the implicated mechanisms remain unclear. In the present study,
we address this relationship and investigate the influence of adipocytes secretome on B16-F10 and
MeWo melanoma cell lines. Using the 3T3-L1 adipocyte cell line, as well as ex vivo subcutaneous
(SAT) and visceral (VAT) adipose tissue conditioned medium, we were able to show that adipo-
cyte-released factors play a dual role in increasingmelanoma cell overall survival, both by enhancing
proliferation and decreasing apoptosis. B16-F10 cell migration and cell-cell and cell-matrix adhe-
sion capacity were predominantly enhanced in the presence of SAT and VAT released factors. Me-
lanocytes morphology andmelanin content were also altered by exposure to adipocyte conditioned
medium disclosing a more dedifferentiated phenotype of melanocytes. In addition, exposure to adi-
pocyte-secreted molecules induced melanocytes to rearrange, on 3D cultures, into vessel-like struc-
tures, and generate characteristic vasculogenic mimicry patterns. These findings are corroborated
by the released factors profile of 3T3-L1, SAT, and VAT assessed by microarrays, and led us to high-
light the mechanisms by which adipose secretome from subcutaneous or visceral depots promote
melanoma progression.
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2.1 Background
Obesity prevalence has significantly increased worldwide, (163) leading to a public health concern
and branded as “the modern epidemic”. (53,163) The prevalence of obesity in Europe has increased by
approximately 30% over the past 10 years and this phenomenon is corroborated by data from several
other countries. (164) It has long been recognized that excess adipose tissue (AT) increases the risk
of cardiovascular disease, type 2 diabetes and metabolic syndrome, (53,163) but only in the past few
decades it became widely accepted that augmented body adiposity is a risk factor for several types
of malignancies. (165,166) Additionally, obesity can lead to worsened prognosis, poorer treatment out-
come and increased cancer-related deaths. (61)
Cutaneous melanoma incidence rates have increased in the last decades worldwide from 3% to
7% annually. (2) These statistics suggest a doubling of rates every 10-20 years, (3,4) raising melanoma
to the most rapidly increasing cancer in Caucasians. (4) Several reports showed positive associations
between increased body fat and the risk of cutaneous melanoma later in life, (65,167–169) suggesting
that the increasing incidence of melanomamay be related to the enlarged obesity prevalence.
In vivo adiposity-related stimulation of melanoma growth has been demonstrated. (77,144,145,160)
Tumour-associated macrophages (144,145) and endothelial cells (145) have been pointed out as possi-
ble mediators in the growth-promoter effect of adipose tissue towards melanomas. In fact, tumour
stroma comprises many different cell types, including fibroblasts, adipocytes, immune and endothe-
lial cells that, along with the extracellular matrix, are key players in cancer development and progres-
sion. (18,170)However, we hypothesize that adipositymight also exert a direct effect overmelanocytes
without the involvement of stromal cells in a paracrine or endocrine manner. Herein, we explored
the biological role of adipocytes secretome in B16-F10 andMeWomelanoma cell survival and plas-
ticity.
2.2 Materials &Methods
2.2.1 Cell Culture and In VitroTreatments
ThemousemelanomaB16-F10cells exhibit in vitro amixedmorphologyof spindle-shapedandep-
ithelial-like cells. It was originally isolated frommelanoma of the C57BL/6J mouse strain. B16-F10
is ametastatic variant of B16melanomaswith high tropism for lung invasion. The humanmelanoma
cell lineMeWowas originally derived and established in culture from a lymph nodemetastasis from
a 78-year-oldmale patient. MeWo is also ametastatic cell line. Similarly to B16-F10 it also resembles
moderate lung invasion ability.
B16-F10 murine melanoma cell line (ATCCCRL-6475), MeWo human melanoma cells (ATCC
HTB-65), and 3T3-L1 pre-adipocytes (ATCCCL-173) were maintained in Dulbeco’s modified Ea-
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gle’s medium (DMEM; Sigma-Aldrich), human dermal microvascular endothelial cells (HMEC)-1,
ATTC CRL-3243) were cultured in RPMI-1640 (Sigma-Aldrich) containing 10 ng/mL epidermal
growth factor (BD Biosciences) and 1 μg/mL cortisone (Sigma-Aldrich). Both media formulations
were supplemented with 10% heat inactivated fetal bovine serum (FBS; Sigma-Aldrich), 1% penicil-
lin/streptomycin/amphotericin B (Sigma-Aldrich). Cells were grown at 37 °C under a humidified
5%CO2 atmosphere. Cells were serum-deprived during 16h before incubation with each treatment
for every experiment. Unless otherwise specified, all treatments and controls were carried out in
serum-free conditions.
2.2.2 AdipocyteDifferentiationandConditionedMediumCollection
3T3-L1 pre-adipocytes were harvested and allowed to reach confluence. After 2 days (day 0), the
differentiation was initiated by addition of a hormonal mixture composed of 2 μM insulin (Sigma-
Aldrich), 1 μM dexamethasone (Sigma-Aldrich) and 0.25 mM isobutylmethylxanthine (Fluka) in
complete medium. Three days later (day 3), the induction medium was replaced by complete
medium supplemented with insulin only. At day 7, cultures with a differentiation yield higher than
80% were washed with phosphate buffered saline (PBS) and incubated in serum-free DMEM. After
24h (day 8), the conditionedmedium (CM) was harvested from the adipocytes cultures, spun for 5
minutes at 300g and the supernatant was stored at -80ºC for the subsequent treatments.
2.2.3 Adipose Tissue Organ Culture
Fragments (8-10mg) from visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT)
depots were collected from 8-week-male C57BL/6Jmice. The fragments were then washed with 1%
penicillin/streptomicyn/amphotericin B (Sigma-Aldrich) in PBS and cultured afterwards in 1 mL
of DMEM supplemented with 10% FBS.The fragments were serum-deprived and 24h later the CM
harvested and centrifuged at 300g for 5 minutes.
2.2.4 Mouse Adipokine Array Analysis
Mouse adipokine antibody arrays (#ARY-013; R&Dsystems)were performedusing 1mLof 3T3-
L1, SAT andVATCMand following themanufacturer’s protocol. The pixel density of each spot was
calculated with the microarray profiler plugin of the ImageJ software (NIH).The relative adipokine
levels were calculated upon normalization with the adipokine levels of B16-F10 CM.
2.2.5 Cell Viability Assay
Tomeasure B16-F10metabolic activity, after a 24h incubation of 1 104 cells/mLwith the differ-
ent treatments, 20 μL of the MTS reagent, from CellTiter 96 Aqueous assay (Promega), was added
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into each 96-plate well followed by a 3 hour incubation period. Color development was determined
by measuring absorbance at 490nm.
2.2.6 Apoptosis Assay
Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labelling
(TUNEL) assaywas performed inB16-F10 cells (1104 cells/mL), after 24h incubationwith the dif-
ferent treatments using the In SituCell DeathDetectionKit (RocheDiagnostics) following theman-
ufacturer’s protocol. Nuclei were counter-stainedwithDAPI (RocheDiagnostics) and immunofluo-
rescence was visualized under a fluorescence microscope (Nikon). The percentage of TUNEL-pos-
itive cells was evaluated by counting the cells stained with TUNEL divided by the total number of
DAPI-stained nuclei at a 200magnification field. One thousand nuclei were evaluated. The results
are presented as mean±standard error of the mean (SEM).
2.2.7 BrdU Proliferation Assay
B16-F10 cells (1104 cells/mL)were culturedwith standard treatments in serum-free conditions
for 20h. Then bromodeoxyuridine (BrdU; Roche Diagnostics), at a final concentration of 0.01 mM,
was added to eachwell for 4h. Thedetectionwas performed using the colorimetric Cell Proliferation
ELISA, BrdU (Roche Diagnostics), according to the manufacturer’s instructions.
2.2.8 Cell Spreading and Adhesion Determination
To determine cell spreading and adhesion, (171) B16-F10 cells were re-suspended in the different
treatments at a final concentration of 5 104 cells/mL, seeded in a 24-well microplate and allowed to
adhere and spread for 3 hours and thenwashedwith PBS to remove non-adherent cells. Fixationwas
performed with 4% (w/v) p-formaldehyde in PBS. Afterwards 200 μL of crystal violet 0.1% (w/v)
was added to each well for 20 minutes and later washed withH2O. To evaluate the morphologic pa-
rameters (cell area, sphericity, size and perimeter) 1000 cells were analysed by CellProfiler software
(Broad Institute) on photographs of random fields, for each treatment, captured under an inverted
microscope (Nikon) at a 200magnification. To determine cell adhesion, the above protocol was
reproduced but only allowing cells to adhere for 30 minutes. Afterwards, crystal violet dye was solu-
bilized in 100 μL 10% (v/v) acetic acid (Fluka) and the absorbancemeasured at 570nm using a plate
reader.
2.2.9 Adhesion to Endothelium Evaluation
HMEC-1cellswere cultured in a24-wellmicroplatewith glass coverslips andallowed to reach con-
fluence. Mediawas aspirated and themonolayerswerewashedwithPBS.Afterwards 1105 cells/mL
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B16-F10 cells, in the different treatments, were added to the wells for 30min. To remove non-adher-
ent cells, the wells were washed with PBS. Fixation was performed with 4% (w/v) p-formaldehyde
for 10 minutes. Coverslips were then stained with Giemsa’s stain, thoroughly washed in Sorensen’s
phosphate buffer andmounted on amicroscope slide. Using a lightmicroscope (Nikon) the number
of cells adherent to the endothelial monolayer were counted in 5 random fields.
2.2.10 Melanin Content Determination
B16-F10 cells (5 105 cells/mL), were incubated with the different treatments for 24 hours. Fol-
lowing detachment with 0,5% trypsin, cell density was assessed on a haemocytometer. After 300g
centrifugation for 10min, the pellet was washed twice with PBS and the melanin was solubilized in
1.0 mL of 1M NaOH (Panreac) containing 10% (v/v) dimethyl sulfoxide (Merck). Next, the ab-
sorbance at 475nm was recorded. Results represent the mean absorbance (±SEM) of 1 106 cells.
2.2.11 TranswellMigration
Migration capacity was quantified on 24-well plates with 8 μm-pore transwell inserts (BD Bio-
sciences). B16-F10 cells (5  104 cells/mL) were harvested on inserts in serum-free medium and
placedonwells containing the standard treatments plus 10% fetal bovine serum(FBS) for 24h. Mem-
branes were then stained with crystal violet 0.1% (w/v) and visualized under a light microscope
(Nikon). Five random fields of eachmembrane were counted on themicroscope (Nikon) at a 100
magnification.
2.2.12 Injury Assay
To perform the injury assay, melanoma cells at confluence were scrapped from the culture dish
using a pipette tip, which left a void space. Cells were then incubated for 24h following the stan-
dard treatments. After this period, damage recovery was then visualized and photographed under
an inverted microscope (Nikon) at a 200 magnification. The wound closure was determined by
measuring the wound area and by subtracting this value from the initial void space (CellProfiler soft-
ware; Broad Institute). Shown are the means values (±SEM) of nine measurements for each time
point and condition.
2.2.13 Matrigel Cultures
To perform Matrigel cultures, 24-well plates were coated with 250 µL per well of Matrigel Base-
ment Membrane Matrix (Corning). Afterwards, B16-F10 (5  104 cells/mL) or MeWo (20  104
cells/mL) melanocytes harvested in the respective treatments were fed on top of the Matrigel layer.
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Cell growth was then monitored and photographed under an inverted microscope (Nikon) at a
200magnification for 24h.
2.2.14 Soft-Agar Colony Formation
The bottom of each 12-well plate was coated with 2 mL of 0.5% agarose and DMEM 2. After
polymerization the wells were fed with 5  103 B16-F10 cells in 2 mL of 0.2% agar and DMEM 2.
The medium was changed every 2-3 days. After 15 days, the wells were stained with 0.01% crystal
violet and photographed. The number and area of the colonies was assessed with ImageJ software
(NIH).
2.2.15 Hanging-Drop Cell Cultures
Generation of melanoma spheroids was conducted as previously described. (172) Briefly, 2:5 106
B16-F10 or MeWo cells/mL were collected in the respective treatments and pippeted to the lid of a
60mmnon-adhesive petri dish leaving 10 μLdrops onto the bottomof the lid. The lidswere inverted,
placed on top of the PBS-filled bottom chamber of the dish and incubated for 3 days.
2.2.16 Statistical Analysis
Results are expressed as mean±SEM. Data were analysed with GraphPad Prism 6.0 (GraphPad
Software Inc.). Differences between samples and parameters among two experimental groups were
evaluated by Student’s t-test. When three or more conditions were evaluated, statistical analysis was
conducted through one-way ANOVAwith Sidak post-hoc test. Significance was set at P < 0:05.
2.3 Results
2.3.1 3T3-L1SecretomeIncreasesMelanocytesSurvival, Proliferation
andMelanin Content, and Decreases Apoptosis
3T3-L1 preadipocytes are a commercially available cell line for studying adipogenesis. (173,174)
Their differentiation, in culture, into mature adipocytes is well widespread and can be achieved by
established protocols. We used CM from fully differentiated 3T3-L1 cells to explore the potential
effects of adipocytes secretome over malignant melanoma B16-F10 cells viability, proliferation, and
apoptosis.
We first analyzed the effects of this conditioned medium in melanoma cells viability by the MTS
assay. After a 24h exposure to adipocyte CM, melanoma cells showed a 48% increase in their meta-
bolic activity (Fig. 2.1a). We found as well that the fraction of proliferating B16-F10 cells was signif-
24
chapter 2 adipocyte secretome in melanoma progression
B1
6-
F1
0
vi
ab
ili
ty
(%
of
co
nt
ro
l)
Control 3T3-L1 CM
0
50
100
150
200
*
Control 3T3-L1 CM
0
100
200
300
B
16
-F
10
pr
ol
ife
ra
tio
n
(%
of
co
nt
ro
l)
*
B
16
-F
10
ap
op
to
si
s
(%
of
co
nt
ro
l)
Control 3T3-L1 CM
0
50
100
150
*
B
Control 3T3-L1 CM
0.00
0.02
0.04
0.06
0.08
0.10
M
el
an
in
co
nt
en
t
(A
BS
/1
x1
06
ce
lls
)
*
A
DC
Figure 2.1: 3T3-L1 secretome increasesmelanoma cell survival. B16-F10 cells were incubatedwithCM from
differentiated 3T3-L1 cells cultures (3T3-L1 CM) or untreated (Control) for 24h. A) An increase in the per-
centage of viablemelanoma cells was observedwhen comparedwith control. Results represent the percentage
of viable cells normalized by the absorbance of control. B)The number of proliferating cells, incorporating
BrdU, increased in thepresence3T3-L1CM.Results represent thepercentageof proliferating cells normalized
over the absorbance of control. C) A significant decrease in the percentage of apoptotic cells was observed
when melanocytes were treated with 3T3-L1 CM. Results represent the percentage of apoptotic cells evalu-
ated by the ratios of TUNEL-positive cells versus total DAPI-counterstained nuclei. D)Themelanin content
per cell was significantly decreased when melanocytes were cultured in presence of 3T3-L1 CM. Melanin
concentration was calculated by determination of OD 475. Results represent the absorbance of 1  106 cells.
(P < 0:05 vsControl; n=9)
icantly increased, as shown by the higher BrdU incorporation, in the presence of these adipocyte-re-
leased factors (Fig. 2.1b). The effect of 3T3-L1 secretome on apoptosis was examined usingTUNEL
analysis. Concomitantly, 3T3-L1 CM medium decreased B16-F10 programmed cell death by ap-
proximately 50% (Fig. 2.1c). These effects were further accompanied by a significant reduction in
melanin content per cell (Fig. 2.1d).
2.3.2 Adipocyte Secretome Profile Characterization
Theprevious findings imply that adipocytes released factors stimulatemelanoma cell viability and
aggressiveness. Therefore, we then assessed the secretion profile of adipocytes to further elucidate
the involvement of adipose tissue inmelanoma behavior (see Supplemental data). Given thewell-es-
tablished distinct biological andmetabolic roles of subcutaneous (SAT) and visceral (VAT) adipose
tissue, microarray assay was performed not only in 3T3-L1 cells, but also in organ cultures of SAT
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Figure 2.2: Secretion profiles of 3T3-L1 cells and subcutaneous and visceral AT organ cultures. A) Both
SAT and VAT CM exhibit greater levels of vascular endothelial growth factor (VEGF) and endocan with a
concomitant reduction in the expression of tissue inhibitor of metalloproteinases (TIMP)-1. B)Distinct rel-
ative levels of interleukin (IL)-6, IL-11, and leukaemia inhibitory factor (LIF) were found among SAT and
VAT CM. C) Adipokines leptin and resistin are overexpressed in all CM, whereas adiponectin levels are sig-
nificantly reduced. D)Numerous cellular growth factors were present at considerably higher concentrations
in both VAT and SATCM. (P < 0:05 vsControl;#P < 0:05 SATCM vs VATCM; n=2).
and VAT fragments.
As illustrated in Figure 2.2, the secretion patterns of numerous growth-factors, adipokines, cy-
tokines, and angiogenesis-related molecules are different among the different CM. Greater levels of
VEGF and endocan were found in SAT and VATCM, whereas TIMP-1) levels were significantly re-
duced in these twoCM(Fig. 2.2a). On the other hand, 3T3-L1CMexhibited higher levels of VEGF,
TIMP-1, and endocan than B16-F10-CM (Fig. 2.2a). The levels of the IL family of cytokines: IL-6,
IL-11, and LIF were also significantly overexpressed within SAT and VAT, although no substantial
differences were found in the 3T3-L1 CM (Fig. 2.2b). Nonetheless, monocyte chemotactic pro-
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tein (MCP)-1 and plasminogen activator inhibitor (PAI)-1 expressionwas upregulated in everyCM
(Fig. 2.2b). AT hormones were also identified. Resistin and leptin relative expression levels were
higher in 3T3-L1, SAT, and VATCM. In addition, retinol binding protein (RBP)-4 was significantly
released in SAT and VAT, but not in 3T3-L1 CM. Interestingly enough, a significant reduction in
adiponectin levels was observed in all CM (Fig. 2.2c). The levels of several growth factors involved
both inmetabolism and in cell behavior were also analyzed. VATCMrevealed the higher expression
of fibroblast growth factor (FGF)-21, insulin-like growth factor-binding protein (IGFBP)-5, hepa-
tocyte growth factor (HGF), insulin-like growth factor (IGF)-1, IGFBP-2, IGFBP-3, and IGFBP-6
levels were significantly higher in SAT than VATCM (Fig. 2.2d).
2.3.3 SATandVATDistinctivelyModulateMelanocyteMigrationand
Cell Spreading
According to the previous secretome profile, TIMP-1, an inhibitor of extracellular matrix degra-
dation was significantly decreased, whereas several inflammatory cytokines and angiogenic growth
factors were upregulated particularly in SAT and VAT. These findings led us to evaluate the influ-
ence of CM in melanocytes motility. We first analyzed whether 3T3-L1 CMmechanically induced
a wound to B16-F10 confluent cultures by injury assay. As illustrated in Figure 2.3a, the resulting
void area was promptly occupied by melanocytes upon 3T3-L1 CM incubation in comparison to
untreated B16-F10 cultures. Following a 24h incubation with CM, the migrated distance is almost
twice the distance of the control treatment as seen by the microscopic examination of the wounds
(Fig. 2.3b). We then examined the effect of SAT and VAT fat depots secretome in B16-F10 cells
motility. In the double-chamber migration assay, the number of migrating cells following a chemo-
tactic gradient was significantly enhanced in every treatment as compared to untreated B16-F10
cultures (Fig. 2.3c). However, SAT CM exerted this effect into a much larger extent. Cell spread-
ing evaluation revealed that VAT and 3T3-L1 secreted molecules, but not SAT, induced spreading
dynamic of B16-F10 cells (Fig. 2.3d). In addition, VAT CM-treated B16-F10 cells exhibited signifi-
cantly higher areas and perimeter, whereas a smaller number of round shaped cells were observed. In
contrast, SAT secreted factors did not significantly alter B16-F10 spread plasticity (Fig. 2.3e). These
findings highlight a distinct paracrine role of AT depots regarding B16-F10 locomotive behavior:
although SAT-released factors boost melanoma cell chemotaxis, VAT CM signalling enhance cell
morphological plasticity and haptotactic spreading.
2.3.4 ATSecretomeModulatesMelanomaCellsAdhesionandTumouri-
genesis
Decreased cell-cell adhesion and anchorage-independent growth are prominent features neces-
sary for successful metastization. (170,175) Therefore, we evaluated the adhesion of CM-treated B16-
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Figure 2.3: In vitromotility, migration and spreading analysis of B16-F10 melanocytes. A) A rapid B16-F10
cell migration was observed after incubation with 3T3-L1 CM in comparison to untreated (Control) for 24h.
Cell cultures were visualized under an inverted microscope at a 200 magnification. B) When exposed to
3T3-L1 CM, melanocytes rapidly occupied the injury-created void area. The wound closure was determined
by measuring cultures void area and by subtracting it from the initial area of the wound. Bars show the means
values (±SEM) of nine measurements for each time point/condition. C)The effects of AT secretome on cell
migrationwere quantified in a double-chamber assay using FBS as a chemoattractant. Thenumber of cells that
invaded themembranewas significantly higherwhen treatedwith 3T3-L1, and particularlywith SATandVAT
CM.Meanvalues (±SEM)of three independentmeasurements are shown(P < 0:05 vsControl;#P < 0:05
SAT CM vs VAT CM; n=3). D) B16-F10 cells were allowed to adhere and spread for 3h in the standard
treatments. Representative images of crystal-violet stained melanocytes are shown (200). E)Morphologic
analysis of B16-F10 cells revealed that VAT and 3T3-L1 CM significantly enhanced cell spreading. Bars are
the means values±SEM, represented as percentage of Control, of 1000 evaluated cells (P < 0:05 vsControl;
n=9)
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F10 cells to standard cell culture plates. Interestingly, B16-F10 cells adhesion was significantly in-
creased after incubation with every CM, being higher upon VATmedium exposure (Fig. 2.4a).
Identical findings were observed in B16-F10 cells adhesion to endothelial cells (Fig. 2.4c). The
number of B16-F10 cells adherent to HMEC-1 monolayers was significantly enhanced both after
SAT and VAT CM treatments as compared to untreated cells or to cells treated with 3T3-L1 CM
(Fig. 2.4b), being the highest increase found upon VAT CM incubation. These findings confirm
that VAT improves B16-F10 adhesive properties. Conversely, in the soft-agar clonogenic assay, SAT
soluble factors promoted the anchorage-independent proliferation of B16-F10 cells upon culture in
non-adherent conditions (Fig. 2.4d and e), whereas exposure to VAT CM did not exert any effect.
SAT released factors increased the number of colonies formed, but not in a statistically significant
manner (Fig. 2.4f). These results further emphasize the divergent roles of SAT and VAT towards
melanocytes malignancy.
2.3.5 AdipocytesSecretedFactors InduceMalignantMelanocytesVas-
culogenicMimicry
Given that malignant melanomas are highly vascularized tumours (85,176) and metastatic mela-
noma cells actively participate in tumour vascularization, (16,176) we next addressed whether CM
from 3T3-L1 adipocytes prompted B16-F10 melanoma cells toward vasculogenic mimicry.
In comparison to untreated cells, 3T3-L1 CM-treated B16 cells rapidly assembled into capillary-
like structures when cultured in Matrigel basement matrix (Fig. 2.5a). To further confirm the three
dimensional growth and spatial arrangement of the melanoma cells, B16-F10 cells were cultured in
hanging-drops for 72h. Microscopic observation of the generated spheroids upon incubation with
3T3-L1 CM revealed the formation of large and diffused aggregates of B16-F10 cells, whereas in the
control treatment, a spherical and compact mass of melanocytes was observed (Fig. 2.5b). Next, we
used MeWo cell line to additionally examine the vasculogenic mimicry inducer effects of 3T3-L1
CM in human melanoma cells. MeWo cells, when cultured on top of Matrigel and in the presence
of 3T3-L1 CM displayed the same vessel-like rearrangement already observed for B16-F10 mela-
nocytes (Fig. 2.5a). MeWo spheroids further revealed a loophole growth pattern when exposed to
3T3-L1-released factors (Fig. 2.5b). Altogether, these findings regarding cell-cell adhesion and reor-
ganization into vessel-like structures formation provide additional support and reinforce the delete-
rious effects of fat-secreted molecules on melanoma tumour progression.
2.4 Discussion
Emerging evidence indicates that systemic factors, including inflammatory, angiogenic or meta-
bolic markers, significantly influence tumour behavior. (177)
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Figure 2.4:Melanoma cells adhesion and achorage-independent growthwere increased after incubationwith
AT CM. A) Adhesion to culture plates for 30 min. B) Adhesion to HMEC-1 monolayers for 30 min. VAT-
released factors were prominent in enhancing melanocytes adhesive potential both to cultures plates and en-
dothelial cells. Results are expressed as percentage of Control (±SEM).C) Representative images (800) of
Giemsa stained slides showing B16-F10 cells (dark blue) adherent to HMEC-1 monolayers (pink). (D) Eval-
uation of anchorage-independent proliferation of B16-F10 melanocytes was conducted by soft-agar colony
formation assay. E) The number of colonies formed was significantly higher in both 3T3-L1 and SAT CM
treatments but not in VAT CM. F)Mean B16-F10 colony area was significantly increased after 3T3-L1 CM
incubation, but not after VAT or SAT CM treatment. Bars represent means±SEM (P < 0:05 vs Control;
#P < 0:05 SATCM vs VATCM; n=3-9).
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Figure 2.5: Vasculogenicmimicry bymelanoma cells was stimulated byATCM.A)B16-F10 andMeWo cells
were cultured on top ofMatrigel layers. Upon treatment with 3T3-L1CM,melanocytes acquired a vessel-like
tubular phenotype. Imageswere captured under an invertedmicroscope (200) at 12 and 24h post treatment.
B)Microscopic examination of B16-F10 andMeWo spheroids in hanging-drop cultures. The presence of 3T3-
L1 secreted factors inhibited the formation of a compact spheroid cellular mass. Shown are representative
light-microscopy photographs (80) of the spheroids.
The current study reveals that adipocyte-released factors increase B16-F10 melanoma cells via-
bility, proliferation, and reduces apoptosis and melanin content. Exposure to adipose tissue CM of
these cells further resulted in increasedmotility, enhancing the capacity tomigrate and spread. These
findings were accompanied by an augmented adhesion capacity, in particularly to endothelial cells,
and anchorage-independent proliferation as assessed by soft agar assays. We further identified the
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factors that are releasedby adipocyte cells of different depots, and revealed that several pro-inflamma-
tory factors (IL-6, IL-11, LIF, andPAI-1),metabolicmarkers (IGFBPs, FGF-21), angiogenic growth
factors (endocan, HGF, VEGF, IGF-I), and hormones (leptin, resistin, RBP-4) were secreted to the
medium into a high extent, whereas TIMP-1, an inhibitor of ECM degradation, and adiponectin
were significantly downregulated.
Adipose tissue is no longer considered a mere lipid store depot, but also an inflammatory and
endocrine organ. (52,60) Accordingly, obesity provides a chronic low grade inflammatory condition,
further potentiated by the presence of hormone cues and cytokines, which are strongly associated
with disease. Therefore, the presence of high amounts of pro-inflammatory cytokines and hormones
in adipocyte CM is expected. Remarkably, the majority of these factors are known to play a role in
cell proliferation, apoptosis,migration, and invasiveness, aswell as adhesion capacity. Recently, it has
been reported that both leptin and resistin, two adipocyte-released hormones, were able to stimulate
melanoma cell growth and proliferation through AKT and fatty acid synthase modulation. (74) In
addition to these hormones, FGF-21, a metabolic regulator also increases cell proliferation in vitro
and increased tumourigenesis and invasive potential in vivo. (178) Likewise, FGF and IL-6 are known
to be produced bymelanoma cells and stimulate proliferation in a autocrinemanner, although other
paracrine growth factors (HGF, IGF-I, and VEGF)modulate themicroenvironment and potentiate
tumour growth and invasion. (138,179) We have found that adipose tissues CMhave significant higher
levels of the above growth factors, reinforcing our findings concerning the effect of CM from the
distinct adipose tissue depots studied in augmenting B16-F10 cell proliferation, migration, ability to
invade, and decreasing apoptosis.
Along with the progression of melanoma, malignant melanocytes dedifferentiate losing most of
their epithelial characteristics through a process similar to epithelial-mesenchymal transition, (180)
leading thus to more aggressive phenotypes. (181) Melanogenesis is an inherent process in melano-
cytes. Melanocytes respond to the inflammatory cytokines, namely IL-6, with a dose-dependent
inhibition of melanogenesis. (182) Nevertheless, whenever these cells exhibit a more malignant phe-
notype, melanocytes decrease melanin synthesis. (20) Our findings show that when treated with CM
from adipocytes, the melanin content per B16-F10 melanocyte was significantly reduced, further
enlightening the growth-promoter and dedifferentiation paracrine effects of adipocytes.
Furthermore, active locomotion of tumour cells is fundamental to malignant invasive and meta-
static capacity. (183–185) By crossing tissue stroma and the vascular bed, tumour cells interact with
both extracellular matrix and soluble tropic factors. Our findings showed that chemotactic migra-
tion of B16-F10 cells was enhanced upon exposure to SAT released factors although cell spreading
and haptotactic migration of tumour cells were positively modulated by visceral-fat secretome. In-
tercellular adhesion is reduced in many aggressive tumours, (175) allowing cells to detach from the
primary lesion and metastasize to distant organs. Again, we found discrete effects among subcuta-
neous and visceral fat depots on B16-F10 adhesive properties. In fact, several biological, metabolic,
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and secretory differences distinguish intra-abdominal visceral adipocytes from peripheral subcuta-
neous adipose tissue. (186,187) In agreement, our results unveileddistinct effects of SATandVATupon
melanocytes aggressiveness. SAT CM enhances B16-F10 locomotion and anchorage-independent
proliferation. In turn, VAT prominently improves melanocytes cell-substratum adhesion. Despite
the higher release of visceral-fat pro-inflammatory cytokines, (186) subcutaneous fat depots, which
are located close to melanoma lesions, influence themalignant transformation of melanocytes. Nev-
ertheless, our microarray assay revealed that the secretome profile of SAT and VAT is significantly
different regarding someof the inflammatory, hormonal, andmetabolicmolecules addressed. TIMP-
1 and IGF-I are chemotactic agents for human melanoma cells that mediate motility. (179,188) IGF-I
was significantly higher in SAT CM although TIMP-1 was under expressed in the adipose tissues
CM. PAI-1 is also known to modulate cell adhesive properties and its overexpression is correlated
with the metastatic capacity of melanomas. (189) Antagonistically, IGFBPs inhibit melanoma migra-
tory and invasive behavior, and induce melanocytic differentiation (190) counterbalancing the IGF-I
effects and most likely contribute to the discrete differences observed between subcutaneous and
visceral CM.The effect of the different AT depot secretome in tumour cells behavior is beyond the
scope of this study, however, our results reinforce the need for additional molecular studies to inves-
tigate how SAT and VAT affect tumour progression.
Accumulating data point outmechanisms associating obesity tomelanoma. (77,80,160,167,168,191) Re-
cent reports unveiled the involvement of high-fat diet-induced increased cytokines and angiogenic
factors in the crosstalk between tumour cells and macrophages. (60,144,145,192) Recruitment of the im-
mune system cells, which release factors that enhance tumour plasticity and themaintenance of stro-
mal microenvironment, has already been described for other malignancies. (193,194) In contrast, our
in vitro results disclose a direct effect of adiposity onmelanoma cells, without the influence of either
tumour-associated cell-mediated immunity or endothelium.
Vascularization plays a central role in tumour development and progression. Besides angiogen-
esis, vasculogenic mimicry provides an alternative, angiogenic-independent tumour microcircula-
tion. (16,25,26) Melanoma cell-lined vascular networks sustain a redundant blood supply required for
both growth andmetastasis. (25,26) Thepresence of these functional vascular channels by the tumour
itself is a predictor of poor prognosis in human melanoma patients (27,28) and might circumvent the
effectiveness of anti-vascular drugs and antiangiogenic therapies. (195) Fully differentiated 3T3-L1
adipocytes CM were able to induce malignant melanocytes to rearrange on Matrigel cultures into
vessel-like structures typically reported for endothelial cells. (196) Moreover, microscopic inspection
of B16-F10 and MeWo spheroids, obtained by hanging-drop cultures, revealed the same pattern of
vasculogenic mimicry observed in cultures of human melanoma cell lines. (25,197) Data confirming
melanoma angiogenesis stimulation byAT tropic factors has recently been highlighted. (144,145)How-
ever, we report for the first time supporting evidence endorsing the potential adipocyte secretome in-
ducer effects of tumour vasculogenic mimicry. Accordingly, several angiogenic growth factors were
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significantly higher in CM, including HGF and VEGF. HGF was involved in vascular mimicry of
hepatocellular carcinoma. (198) Additionally, VEGF signalling was found to be involved in vascular
mimicry through activation of VEGFR1 expression inmelanoma cells, (199) explaining the increased
capacity of melanoma cells to form vasculogenic structures after treatment with adipocyte CM. En-
docan, in turn, is a new tumour invasion and angiogenic marker, being overexpressed in tumour ves-
sels. (200) The fact that it is upregulated in both SAT and VAT conditioned mediummay also explain
the involvement of adipose tissues in tumour aggressiveness.
Altogether, our results indicate that adipocytes secretome induce malignant melanocytes aggres-
siveness. The synergic increase inmelanocyte survival, adhesion, motility, and plasticity allied to the
stimuli for cell-cell networks of vasculogenic mimicry patterns, support the deleterious effects that
adiposity partakes directly in melanoma progression.
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2.6 Supporting Information
Table 2.s1: Gene expression profile of secretomes from 3T3-L1, SAT and VAT by microarray
Adipokine 3T3-L1 SEM SAT SEM VAT SEM
Adiponectin 0,79 0,30 0,63 0,01 0,53 0,02
AgRP 1,53 0,04 1,04 0,00 1,15 0,02
ANGPT-L3 1,35 0,10 1,58 0,03 1,14 0,13
C-Reactive Protein 1,53 0,10 1,95 0,00 1,72 0,11
DPP-IV 1,73 0,00 4,13 1,33 4,60 2,45
Endocan 1,33 0,04 11,80 0,19 12,76 0,10
Fetuin A 1,05 0,00 1,19 0,12 1,23 0,02
FGF acidic 1,32 0,00 1,11 0,08 1,18 0,02
FGF-21 2,48 0,39 2,57 0,39 7,88 0,51
HGF 5,89 0,02 18,93 1,03 12,28 0,25
ICAM-1 1,36 0,05 1,36 0,02 1,36 0,01
IGFBP-1 1,73 0,48 1,09 0,05 1,14 0,06
IGFBP-2 1,55 0,34 16,62 1,57 4,20 0,61
IGFBP-3 16,50 0,87 26,01 0,06 22,99 0,33
IGFBP-5 8,71 0,54 16,21 0,43 19,71 0,21
IGFBP-6 26,24 0,15 13,84 0,45 9,84 0,86
IGF-I 2,16 0,03 4,06 0,52 2,28 0,14
IGF-II 3,25 0,14 1,01 0,05 1,06 0,06
IL-10 1,18 0,05 1,10 0,15 1,10 0,07
IL-11 1,28 0,13 21,61 1,39 16,38 0,33
IL-6 1,55 0,12 6,68 0,23 10,22 0,16
Leptin 7,81 0,38 3,31 1,28 11,24 0,25
LIF 1,89 0,20 10,14 0,47 12,40 0,14
Lipocalin-2 48,38 3,70 1,91 0,64 1,14 0,15
MCP-1 20,31 0,23 6,53 0,28 7,49 0,25
M-CSF 5,19 0,51 1,98 0,15 2,21 0,08
Oncostatin M 1,75 0,35 1,67 0,04 1,17 0,03
Pentraxin 2 1,43 0,02 1,12 0,08 1,08 0,05
Pentraxin 3 5,78 0,18 1,72 0,16 2,32 0,12
Pref-1 6,21 0,02 1,42 0,06 1,36 0,13
RAGE 1,70 0,12 1,27 0,00 1,30 0,06
Continued on next page
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Table 2.s1: Gene expression profile of secretomes from 3T3-L1, SAT and VAT by microarray
Adipokine 3T3-L1 SEM SAT SEM VAT SEM
Continued from the previous page
RANTES 4,79 0,18 0,93 0,00 1,43 0,04
RBP4 1,91 0,67 12,67 1,74 11,87 0,86
Resistin 23,87 0,09 16,82 0,37 14,43 0,38
Serpin E1 25,29 0,20 11,09 0,50 9,79 0,47
TIMP-1 5,39 0,08 0,30 0,14 0,29 0,06
TNF-α 3,21 0,23 1,69 0,59 1,80 0,12
VEGF 2,24 0,02 1,86 0,02 1,89 0,05
Values are fold-increase relative to fresh medium of each culture. Intensity values are av-
erages of two measurements.
Legend: AgRP: Agouti-related peptide; ANGPT-L3: angiopoietin-like 3; DPP-IV:
dipeptidyl peptidase 4; FGF: fibroblast growth factor; HGF: hepatocyte growth factor;
ICAM-1: intercellular adhesion molecule 1; IGFBP: insulin-like growth factor-binding
protein; IGF: insulin-like growth factor; IL: interleukin; LIF: leukemia inhibitory factor;
MCP-1: monocyte chemotactic protein 1; M-CSF: macrophage colony-stimulating fac-
tor; Pref-1: preadipocyte factor 1;RAGE: receptor for advanced glycation endproducts;
RANTES: regulated upon activation normal T cell expressed and presumably secreted;
RBP4: retinol binding protein 4; TIMP-1: tissue inhibitor ofmetalloproteinase 1; TNF-
α: tumour necrosis factor alpha; VEGF: vascular endothelial growth factor.
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Adipocyte Secretome Increases Radioresistance of
MalignantMelanocytes by Improving Cell Survival
andDecreasingOxidative Status
Coelho P, Silva L, Faria I, Vieria M, Monteiro A, Pinto G, Prudêncio C, Fernandes R and Soares R
Radiation Research 2017; in press
ABSTRACT
Radiotherapy is a treatment option for the majority of malignancies. However, because mel-anoma is known to be radioresistant, the use of ionizing radiation as an adjuvant therapy incutaneous melanoma patients is ineffective. Obesity has now been recognized as a risk fac-
tor for melanoma. High adiposity is generally associated with a more pro-oxidative status. Oxida-
tive stress is a major player in radiation therapy and also a common link between obesity and can-
cer. Several adipocytes-released proteins are known to have a role in controlling cellular growth and
pro-survival signaling. For that reason, we investigated the influence of 3T3-L1 mature adipocyte
secretome in B16-F10 malignant melanocyte radiosensitivity. We evaluated B16-F10 cell survival
and redox homeostasis when exposed to four daily doses of ionizing radiation (2 Gy per day) up to
a total of 8 Gy in a medical linear accelerator. B16-F10 melanocytes exhibited slight alterations in
survival, catalase activity, nitrative stress and total oxidant concentration in the first 2 Gy irradiation.
The motility of the melanocytes was also delayed by ionizing radiation. Subsequent irradiations of
the malignant melanocytes led to more prominent reductions in overall survival. Remarkably, 3T3-
L1 adipocyte-secretedmolecules were able to increase the viability andmigration ofmelanocytes, as
well as lessen the pro-oxidant burden induced by both the single and cumulative X-ray doses. In vitro
adipocyte-released factors protectedB16-F10malignantmelanocytes fromboth oxidative stress and
loss of viability triggered by radiation, enhancing the radioresistant phenotype of these cells with a
concomitant activation of the AKT signalling pathway. These results both help to elucidate how
obesity influences melanoma radioresistance and support the usage of conventional medical linear
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accelerators as a valid model for the in vitro radiobiologic study of tumour cell lines.
3.1 Background
Melanoma is one of the world’s most rapidly increasing malignancies. (1) The number of reported
cases has been increasing for the last few decades. Over 176000 new cases ofmelanoma are reported
annually in Europe and theUS. (5,6)Melanoma treatment has remained the same for the last decades:
surgical excision of themalignantmass is still themost effective treatment in primarymelanomas. (2)
Radiation therapy (RT) is frequently used to treat the majority of malignancies, and has a direct
impact in the proliferative phenotype of both normal and cancer cells. Radiation-induced ionization
of regulatory proteins andDNAmight render the cells unviable and culminate in cellular death. (201)
Ionizing radiation can also indirectly cause cellular damage. The formation of highly reactive oxygen
and nitrogen radicals increases the intracellular oxidative stress, depleting the antioxidant defences,
which subsequently react with many cellular components (DNA, proteins, lipids) leading to unre-
coverable damage. (202)
However,melanoma is known tobe radioresistant, whichdiscourages the use of ionizing radiation
as an adjuvant therapy in melanoma patients. (48) Recently, the use of radiation in higher delivered
doses, hypofractionated and in combinationwith immunotherapyhas led to somepositive outcomes
inmelanomametastasis treatment and palliation. (44,49,50)Nonetheless, obesity, particularly high vis-
ceral adiposity, presents a problem in treatment planning and the delivery of radiation to internal
metastases. Generally, higher body adiposity is associated with both cancer initiation and progres-
sion. (203) Obesity itself is a risk factor for several types of neoplasms, including melanomas. (63,65)
High adiposity can be a contraindication for (and may limit the extent of) cancer surgery, since it
contributes to the inadequate dosing of chemotherapeutic drugs and complicates the planning and
delivery of radiation. (204–206)
Adipocytes secrete a variety of factors that exert effects at both local and systemic levels. (51) The
grand majority of these factors are cytokines, chemokines and inflammatory mediators, but a role
in growth regulation as a new aspect of adipokines has been revealed by novel adipocyte-released
molecules. (69) Fat-derivedmolecules stimulatemelanoma progression and aggressiveness and act as
mediators of proliferation in melanoma cells. (160,207)
Resistance to oxidative stress appears to be a keymechanism of tumour radioresistance. (208)Obe-
sity is linked to amore pro-oxidative status, with a concomitant systemic increase in reactive oxygen
species (ROS), acting as an additional source of oxidants. (55)
For the current study, we hypothesize that adipocytes might lead to two antagonistic outcomes
towards melanocyte radiosensitivity. Although the fat-derived growth factors might protect mela-
nocytes from radiation-induced loss of survival by stimulating their overall proliferation, the adipo-
cyte-generatedoxidants can further increase the oxidative burden, aggravating the radiation-induced
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damages. In this study, we irradiated cell cultures at standard doses investigate the action of adipo-
cyte secretome in melanoma radioresistance. (209)
3.2 Material &Methods
3.2.1 Cell Cultures
B16-F10 melanocytes and 3T3-L1 pre-adipocytes were maintained in high-glucose Dulbeco’s
modified Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal bovine serum
(FBS) and 1%penicillin/streptomycin/amphotericin B (Sigma-Aldrich). Cells were culture at 37ºC
in an incubator with a 5%CO2 humidified atmosphere.
B16-F10melanocyteswere cultured in96well plates (1104 cells/mL) for viability determination
and in 24 well plates (10  104 cells/mL) for the other assays. All treatments were conducted in
serum-free conditions and following a 16 hour FBS-starving period.
3.2.2 Adipocytes Differentiation and Conditioned Medium Collec-
tion
Two days after 3T3-L1 pre-adipocytes cultures reached confluence, a mixture of 2 μM insulin
(Sigma-Aldrich), 1 μMdexamethasone (Sigma-Aldrich) and 0.25mM isobutylmethylxanthine (Flu-
ka) was added to the cultures. The medium was replaced and the cells maintained with 2 μM in-
sulin every two-three days. On the seventh day post-induction, cultures were washed with phos-
phate buffered saline (PBS) and incubated in serum-free DMEM. On the next day, the conditioned
medium (CM), enriched with adipocytes secretome, was harvested from the adipocytes cultures,
centrifuged for 5 minutes at 300g and the supernatant was collected for the subsequent treatments.
3.2.3 Irradiation of Cells
Prior to irradiation, computed tomography scans were performed to obtain three-dimensional
images and calculate the density of both the 24 and 96-well plates. To simulate a biologic structure,
the plates were placed in between two 5cm-height water phantoms (Supplementary Fig. ??).
The three-dimensional conformal RT dosimetric plan comprised two fields (one anteroposterior
and one posteroanterior) and was performed using the software XIO-Release 4.70.02 (Supplemen-
tary Fig. ??). A total dose of 8Gy in 4 daily fractions of 2Gy, prescribed to the isocenter, was delivered
in a PRIMUS, Siemens® linear accelerator with a 6MV photon beam.
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3.2.4 Metabolic Activity Assay
The(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT,Sigma-Aldrich)was used
to assess the metabolic activity of malignant melanocytes (B16-F10) submitted to RT under the in-
fluence of adypocytes secretome (3T3-L1). B16F10 cells were seeded in 96-well plates and cultured
for 24 hours. Afterwards, cells were treated with the mature adipocytes CM and submitted to RT
treatment. Next, 20 µL of MTT was added to each well and incubated for 3 hours. After this pe-
riod, the violet formazan precipitate was dissolved in 100 µL of dimethyl sulfoxide (Merck) and the
absorvance at 550 and 650nm recorded. The results were calculated by the formula ABS(final) =
ABS(550)   ABS(650) and normalized by diving over the absorbance of the control.
3.2.5 Total Antioxidant Status Determination
The in vitro determination of the total antioxidant status (TAS) was done with the TAS kit (Ran-
dox Laboratories) following the manufacturers instructions. Briefly, 5 µL of the sample were mixed
with a 200 µL of the chromogenic solution and the substrate was added to a final volume of 250
µL. The appearance of the radical cation ABTS + was monitored for 15 minutes at 600nm. An-
tioxidants suppress the blue-green color production to a degree that is proportional to their con-
centrations. Calibrationwas performed usingTrolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-car-
boxylic acid) standards and the results were expressed as TASmmol=mL = ConcentrationTrolox standards(ΔABSsamples ΔABSTrolox) where
ΔABS = ABSfinal   ABSinitial, according to the manufacturer instructions.
3.2.6 Catalase Activity
Catalase activity was determined based on the rate of decomposition of H2O2, which is propor-
tional to the reduction of the absorbance at 240nm. A volume of 100 μL of each sample was added
to 400 μL of 5 mM hydrogen peroxide substrate solution in 0.05M phosphate buffer (pH 7.0). The
decay kinetics for absorbance was determined in a Jenway 6505 Uv/Vis spectrophotometer for one
minute. Results are expressed as jΔABS=minj  106.
3.2.7 TBARS Determination
Todetermine thiobarbituric acid-reactive substances (TBARS), 100µLof thiobarbituric acid 10%
(w=v) (Merk) were added to 500 µL of cellular extract and placed in a boiling water bath for 30 min-
utes. Afterwards, the amount ofmalondialdehyde (MDA)presentwas determined bymeasuring the
absorbance at 535 nm. The standard curvewas performedwith standard solutions ofmalonaldehyde
bis(dimethyl acetal)(Sigma).
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3.2.8 Nitrotyrosine Quantification
B16 cell lysateswere prepared inPBS and sonicated for 10min (SilentCrusher S;Heidolph Instru-
ments GmbH). Proteins and other cellular components were precipitated with 15% (v/v) ice-cold
trifluoracetic acid upon centrifugation at 10000 rpm for 10 minutes. Chromatographic detection
of 3-nitrotyrosine (3-NT) was performed as described by Dulce Teixeira and colleagues (in press;
see Supplementary Table ?? for detailed chromatographic conditions). 3-NT standards were pre-
pared from lyophilized 3-Nitro-L-tyrosine (Santa Cruz Biotechnology). The reverse-phase HPLC
VWR-Hitachi Elite LaChrom(VWR)chromatographic systemused consisted of a quaternary pump
model HTA L-2130, an autosampler L-27200, a ODS-Hypersil C18 analytical column (200 cm × 4
mm i.d.; 5 µm particle size) (Merck) in a L-2300 column oven and a diode array detector model L-
2455. The resulting chromatograms (Supplementary Fig. ??)were analyzed usingAgilent EZChrom
Elite 3.3.2 software (Agilent Technologies).
3.2.9 In Vitro Scratch Assay
Using a pipette tip, an injury was inflicted in B16-F10 confluent cultures. Cells were then incu-
bated following 3T3-L1 conditioning and/or RT treatment. At 4, 12 and 24 hours post-treatment,
the migrated distance was photographed under an inverted microscope (Nikon) at a 200magnifi-
cation and the scratch closure was determined by measuring the injury width with Image J software
(NIH). Shown are the normalized values ±standard error of themean (SEM) of ninemeasurements.
3.2.10 Western Blotting Analysis
Proteins were extracted using RIPA buffer from B16-F10 cell lysates. Equal volumes of protein
extracts were loaded onto a 10% SDS-PAGEwith a 5% stacking gel. After electrophoretic separation,
proteins were blotted into a nitrocellulose membrane (Amersham Biosciences). Immunodetection
for total AKT, phosphorylated AKT (Ser473), and β-actin (all Cell Signaling) was accomplished
with enhanced chemiluminiscence (Clarity ECL kit, BioRad).
3.2.11 Statistical Analysis
Statistical analysis was conducted in GraphPad Prism 6.0 (GraphPad Software Inc.). Differences
between treatments were evaluated by Student’s t-test or two-way ANOVAwith Sidakmultiple com-
parisons test accordingly to the number of conditions and treatments. Significance level was set to
P < 0:05.
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3.3 Results
3.3.1 3T3-L1 CM Protects B16-F10 Cells from Radiation Damage
To access the susceptibility of B16-F10 cells to the direct effects of ionizing radiation, B16-F10
melanocytes were irradiated with a single 2Gy dose of X-rays and the cellular viability was then eval-
uated by the MTT assay. Upon irradiation, B16-F10 cells shown a slight (10%) decrease in their
metabolic activity. However, 12 hours after the metabolic activity of the melanocytes exposed to
RTwas improved to control values (Fig. ??a). When cultured with 3T3-L1 CM themalignant mela-
nocytes significantly increased their metabolic activity by more than 30% whether irradiated or not
(Fig. ??a).
Ionizing radiation imbalances the cellular redox homeostasis. (202) Accordingly, we next evaluated
oxidative stress markers and antioxidant status of the irradiated B16-F10 melanocytes.
Lipid oxidation by ROS gives rise to a number of byproducts. MDA is one of the principal end-
products of fatty acid peroxidation in cells. (210) We evaluated the MDA levels by the TBARS assay
but found no significant differences in lipid peroxidation with either irradiation or 3T3-L1 secreted
factors at the two time points studied (Fig. ??b).
Catalase is an oxidative stress protective enzyme that neutralizes hydrogen peroxide formed dur-
ing oxidative stress. The activity of this enzyme in B16-F10 melanocytes was not altered after ex-
posure to ionizing radiation. However, a significantly lower activity was observed when cells were
treated with 3T3-L1 secretedmolecules (Fig. ??c). Incubation with adipocyte 3T3-L1 CM resulted
in a significant increase in catalase activity in the melanocytes 4 h postirradiation.
Although the total antioxidant capacity of 3T3-L1 CM is significantly higher than fresh culture
medium (Fig. ??d), when fed toB16-F10 cultures and irradiated, the number of antioxidants present
in the 3T3-L1 CM is no different from the control 12 h after treatment (Fig. ??e). Interestingly, the
intracellular production of redox scavenger mechanisms is stimulated by the adipocyte secretome
and counterbalances the lower radiation-induced antioxidant defence status (Fig. ??f).
To address the ability of melanocytes to migrate, a mechanical damage was inflicted to confluent
melanocytes cultures and the scratch closure wasmicroscopically inspected (Fig. ??b). Melanocytes
rapidly occupied the injured area when incubated with 3T3-L1 CM. Exposure to radiation (2 Gy)
slowed down B16-F10 motility towards the injury void space, particularly 4 h postirradiation, but
this effect was reversed when 3T3-L1 CMwere also present (Fig. ??a).
These results indicate that adipocyte-released molecules can protect melanoma cancer cells from
X-ray radiation damages, both reducing antioxidant status and enhancing cell migration.
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Figure3.1: B16-F10 survival and antioxidant status upon single 2Gy irradiation and treatedwith 3T3-L1CM.
Controls were treated with serum-free DMEM. A)Metabolic activity of melanoma cells by MTT reduction
assay. Results represent the percentage of viable cells normalized by the absorbance of control. B) Levels of
MDA by TBARS determination in B16-F10 cell lysates. C) Catalase activity was determined based on the
reduction of absorbance at 240 nm.
Total antioxidants concentration in fresh 3T3-L1 CM and DMEM (D) and in the treated B16-F10 culture
supernatant (E) and cellular extract (F) was determined enzymatically by the TAS assay. Shown are mean
values (±SEM) of threemeasurements for each time point/condition. Results are normalized as a percentage
of the control treatment (P < 0:05 vsControl treatment;#P < 0:05 vs irradiation).
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3.3.2 AdipocyteSecretomeContributestoMelanomaRadioresistance
As radiation exposure increases, the amount of direct and indirect oxidative stress-mediated cellu-
lar damages increases proportionally. Our next approach was to determine the effects of cumulative
radiation of B16-F10 melanocytes. A total dose of 8 Gy was delivered in four daily 2 Gy irradiations
to melanoma cells in the presence of the 3T3-L1 adipocyte derived factors.
The metabolic viability of the irradiated melanocytes displayed a constant decrease, of approxi-
mately 20%, for radiation doses greater than 4Gy. However, 3T3-L1 CM treatment of B16-F10 cells
significantly increased the survival of the melanocytes suppressing the radiation-induced cytotoxic
effects (Fig. ??a). Catalase activity followed a similar trend: radiation promotes a diminished basal
catalase activity but when in the presence of the 3T3-L1 CM, catalase activity is highly enhanced
(Fig. ??b).
Reactivenitrogen species (RNS) lead tooxidativeproteinmodifications. Free3-NT is abiomarker
of the turnover of radiation-induced nitrated proteins. (211)The levels of 3-NT rapidly increasedwith
the first cumulative radiation doses, but by the end of the experiment the levels of 3-NT approx-
imated to those of the control group. 3T3-L1 released factors protected irradiated B16-F10 cells
from oxidative nitration primarily in the first radiation fractions (Fig. ??c).
Activationof thePI3K-AKTsignalingpathwayhasbeencorrelatedwith radiation resistance. (212,213)
To investigate whether these radioresistant inducer effects of 3T3-L1 CM were due to activation
of the PI3K-AKT signaling pathway, immunoblotting for AKT and Ser473 phospho-AKT was per-
formed in B16-cell lysates. The expression of the active form of AKTwas only detected in treatment
groups containing the 3T3-L1 CM (Fig. ??d), confirming the stimulation of this pathway by adipo-
cyte-released factors.
These findings further underscore the protective effects of the adipocyte secretome in shielding
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melanocytes from oxidative stress and loss of viability triggered by repetitive fractions of ionizing
radiation.
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Figure3.3: Adipocyte released factors protect B16-F10melanocytes from fractionated radiationdamage. Me-
lanocytes were treated with 3T3-L1 CM, irradiated daily (2Gy) for four consecutive days or received both
treatments (3T3-L1 CM+ irradiation). At 12, 24, 48, 72 and 96 h after the first irradiation, cellular metabolic
activity (A), catalase activity (B) and 3-nitrotirosine content (C) were determined. Results are represented
as percentage of control. Bars showmean±SEM (P < 0:05 vsControl treatment;#P < 0:05 vs irradiation;
n=6). D) Immunoblot detection of AKT and Ser473 phosphorylated-AKT. β-actin was used as a loading con-
trol. A representativeWestern blot is shown.
3.4 Discussion
Cell survival response and (anti)oxidant status are good indicators of radiation susceptibility. Our
results disclosed an increased metabolic activity of irradiated melanocytes when treated with adipo-
cyte CM. Low-dose irradiation (2 Gy) was only able to induce significant alterations in B16-F10
viability in the early hours after treatment. However, repeated irradiation of melanocytes, up to a
total of 8 Gy, led to a constant decrease in metabolic activity. On the other hand, when 3T3-L1
adipocyte secreted molecules were present, radiation-induced loss of viability was overturned and
melanocytes had higher metabolic activities.
Melanocytes are considered to be resistant to radiation damage. (214) Ionizing radiation increases
the oxidative burden in tumour cells. (215) Themild decrease in catalase activity and antioxidant ca-
pacity combinedwith the temporary increase in protein nitrative stress observed corroborate the low
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radiosensitivity of B16-F10 melanocytes. Nevertheless, adipocyte-released factors enhanced the ca-
pacity of melanocytes to fight radiation-induced oxidative stress further contributing to melanomas
radioresistance.
In obese patients there is a shift in the delivery of external-beam radiation, resulting in the target
location not receiving the full dose. (216) In addition to the physical constraints to dose planning and
delivery, our data further reinforce that the adipokine-rich environment might further contribute to
the radioresistance of the melanocytes, culminating in a global underdosing effect. In addition to
careful planning and dose delivery, which must take into account the higher body mass index of the
patients, consideration must also be given to the more pro-inflammatory status and the adipokine
and chemokine-rich environment that can protect malignant cells from the radiation damages.
Oxidative stress has been proposed as a common link between obesity and cancer. The increased
levels of circulating oxidants and ROS produced from peritumoural adipose tissue accelerate oxida-
tive stress within tumour cells and might contribute to the increased risk for cancer progression in
obese patients. (55) ROS production also increases along the differentiation of 3T3-L1 cells into ma-
ture adipocytes, (56) however, our results showed a higher antioxidant capacity of 3T3-L1CM.Given
the short half-life of radicals, this ROS-mediated effect might be less significant in our cell culture
model. In fact, numerous 3T3-L1 adipocyte-secreted proteins have implications in growth regula-
tion and act as cell mitogens. (69,207,217) We believe these pro-proliferative and anti-apoptotic effects
overcome the adipocyte-derived ROS.
Several signaling pathways involved in the radioprotective mechanisms of melanoma have been
identified. MEK, ERK and PI3K-AKT cell survival cascades are known to play important roles in
overcoming the radiation-induced damage (218) and have implications for radioresistance mecha-
nisms in cancer. (212,213) Blockage of these pathways has been shown to radiosensitizemelanocytes to
ionizing radiation. (219) We have already demonstrated that 3T3-L1 CM is rich in numerous growth
factors, (207) such as insulin-like growth factor (IGF)-I and hepatocyte growth factor (HGF), which
have been linked to cancer radioresistance. Downregulation of IGF-1 receptor in mouse mela-
noma B16-F1 cells improved radiosensitivity (220) and, in some malignancies, radioresistance phe-
notypes were aggravated by HGF. (221) IGF-I and HGF signaling activates PI3K-AKT pro-survival
pathways. (222) These findinds led us to assume that the growth-factors present in the 3T3-L1 CM
and the up-regulation of the AKT signaling cascade are contributing to the radioresistant pheno-
type of B16-F10 cells observed in our results. Nevertheless, given the vast number of growth factors
and bioactive molecules released by adipocytes, it is our belief that a “one mechanism fits all” ap-
proach is unlikely to exist and other signalling pathways certainly are co-activated and contribute to
the enhanced radioresistance of melanoma .
Radiation also induces vascular damage that potentiates tumour hypoxia. (223) In a recently pub-
lished study, our group showed that adipocyte secretome enhances vasculogenic mimicry in B16-
F10 cells. (207) Therefore, reducing the vascular network dependence of the tumour for blood supply,
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which allied with the radiation-desensitizing effect, plays a cumulative role towards melanoma ag-
gressiveness.
In summary, our results indicated that an environment rich in adipocyte-released factors con-
tributes to the protection of melanocytes from radiation-induced oxidative stress and viability loss,
circumventing the efficacy of radiation, with a contribution of adipocyte-released factors PI3K-AKT
activation.
Although further in vivo studies are of paramount importance to elucidate the molecular players
involved, the current study demonstrates the importance of taking into consideration the role of
adiposity when planning RT regimens.
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3.6 Supplementary Data
Table 3.s1: Detailed chromatographic conditions for 3-nitrotyrosine detection
HPLCRunning Conditions
Solvents: Methanol, ultrapure water and 2,5% acetic acid (70:15:15)
Elution: Isocratic
Flow: 1,0 mL/min
Injection volume: 30 μL
Column Temperature: 25 ºC
Detection: UV@ 356 nm
Runtime: 15 minutes
Figure 3.s1: 3D Conformal radiotherapy planning CT for the multi-well cell culture plates. A) Axial plane
planning CT with overlay of radiation isodose lines. Coronal (B) and sagittal (C) images. D) Schematic rep-
resentation of the plates arrangement in between thewater phantoms. The red lines represent the laser-guided
alignment to the radiation isocenter.
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Figure 3.s2: Conformal radiotherapy simulation for the multi-well cell culture plates. Axial (A), coronal (B)
and sagittal images (C). The red isodose area represents the fraction dose - 2 Gy. D)Dose volume histogram
summarizing the radiation dose coverage to the target volume.
Figure 3.s3: Representative chromatograms of 3-nitrotyrosine (3-NT) standards (A) or samples (B). 3-NT
elution was detected at 356 nm and displayed a retention time of approximately 9,8 minutes.
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Adipose-Derived Factors Increase
B16-F10 Tumour Vascularization
but DecreaseMetastastatic Potential
Coelho P, Almeida J, Prudêncio C, Fernandes R and Soares R
Unpublished Work
ABSTRACT
Melanoma has one of the most rapidly increasing cancer prevalences and obesity has beenpointed out as a potential melanoma-promoting factor. A small group of reports in theliterature demonstrate that adiposity and fat-released molecules play a role in melanoma
vascularization, including angiogenesis, lymphangiogenesis, and more recently vasculogenic mim-
icry (VM). Both angiogenic vessels and VM channels represent entry points into the vasculature,
allowing tumour cells to hematogenous spread and metastasise. However, the relationship between
obesity and melanoma VM/metastasis is largely unknown. Herein, we employed a high-fat diet
(HFD)-induced obese mice melanoma allograft model, where C57Bl/6J mice were either subcu-
taneously or intravenously inoculated with B16-F10melanoma cells, to investigate the action of adi-
posity in melanoma angiogenesis, VM density and lung colonization. HFD-feeding enhanced mel-
anoma burden, with tumour volume positively correlating with weight gain. Tumour growth was
accompanied with increased microvessel density and area. However, tumour VM density was not
significantly altered upon high-fat feeding. Weight gain was inversely correlated with lung metasta-
tic potential. Significantly fewer lungmetastasis were found inHFD animals than their standard diet
(SD)-fed counterparts, still they exhibited more melanin pigmentation. In vivo fat-released circulat-
ing factors enhanced skinfold melanoma growth and vascularization but, on the other hand weak-
ened the metastasizing capacity of circulating malignant B16-F10 cells. Distinct circulating profiles
of adipokines, growth factors and angiogenic modulators, assessed by microarrays, were associated
to weight gain and led us to highlight possible molecular players for the observed discrepancies.
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4.1 Background
Malignant melanoma is among the most notoriously aggressive and treatment-resistant human
cancers. Even though melanomas comprise less than 10% of all diagnosed skin cancers, melanoma
represents nearly 80% of skin cancer deaths. (80) The incidence of melanoma is continuing to in-
crease year by year in the last decades, (2) with an estimate doubling of incidence rates every 10 to
20 years, (3,4) raising melanoma to the most rapidly increasing cancer in white populations. (4)
Both high-adiposity and obesity have been pointed out as possible underlying causes for the in-
creasing prevalence of human melanoma. Even though systematic reviews estimate a 1.17-1.31 risk
ratio of developing melanoma for overweight and obese populations, (63–65) other reports found no
significant association between obesity and risk for malignant melanoma. (62,66) Therefore, obesity
influence in melanoma still remains controversial.
Nevertheless, in vivo adiposity-related stimulation of melanoma growth has already been demon-
strated. (77,144,145,160) Diet-induced obesity, in rodent models, enhances both melanoma angiogen-
esis and lymphangiogenesis, with the commitment of lymph node metastasis, (145) while in vitro
adipocyte-released factors act as sponsors of melanoma vasculogenic mimicry (VM). (207) Metas-
tasis in melanoma xenografts is associated with primary tumour microvascular density. (99) More-
over, VM is another characteristic microcirculation pattern in melanomas. (25) Melanoma cell-lined
vascular-mimetic networks constitute an additional entry point into the vasculature. However, the
relationship between obesity and melanoma VM andmetastasis is largely unknown.
Dysfunctional adipose tissue production of many adipokines and growth factors is involved in
the growth-promotion and metastatic potential of human cancers. (36,64) Moreover, there is increas-
ing evidence that adipokines play a pivotal role in the dissemination and establishment ofmelanoma
metastasis. (138,224) Accordingly, we propose to address the relationship between high adiposity and
melanoma progression. Employing an high-fat diet (HFD)-inducedC57Bl/6Jmicemodel and B16-
F10murinemalignantmelanoma cells we explored the effects of diet-induced obesity onmelanoma
progression, focusing on tumour angiogenesis, vasculogenic mimicry and lung metastasising capac-
ity.
4.2 Materials &Methods
4.2.1 Cell Culture
MousemelanomaB16-F10 cells, originally isolated fromC57Bl/6Jmelanoma lungmetastasis, are
metastatic skinmelanoma cells line with high tropism for lung invasion. B16-F10 cells (ATCCCRL-
6475) weremaintained inDulbecco’s modified eagle’s medium (Sigma-Aldrich) supplemented with
10%heat inactivated fetal bovine serum(Sigma-Aldrich) and1%penicillin/streptomycin/amphoter-
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icinB (Sigma-Aldrich). Cellsweremaintained at 37 °C in ahumidified5%CO2 incubator. Cellswere
serum deprived for 24 hours before inoculation into the animals.
4.2.2 Animals and Diets
Five-week-old male C57Bl/6J mice were purchased from Charles River (France) and housed at
the animal research facility of Faculty of Medicine of University of Porto. Mice were acclimatized
to the laboratory conditions and provided free access to rodent chow and water. The mice stayed
in quarantine for 10 days before use and were maintained throughout the study in a controlled and
specific-pathogen-free environment: 23 ± 5°C, 35 ± 5% relative humidity, and a 12-hour light/dark
cycle. Afterwards,micewere randomly split and subsequently fedwithoneof twodiets: the standard
diet (SD) and the HFD.The SD (#2014; Teklad Diets) used in this study contained 13%, 67% and
20% of kcal from fat (soybean oil), carbohydrates and protein respectively. The purified HFD (EF
R/Macc. D12451 (I)mod; ssniff Spezialdiäten) contained 45%, 35% and 20%of kcal from fat (lard),
carbohydrates and protein respectively. Fresh diet was freely provided and the animals weight and
food/water intake was monitored throughout the study.
4.2.3 B16-F10 Cell Inoculation
After 26 weeks of diet feeding, both HFD and SD-fed mice were randomly split intro 3 groups:
subcutaneous (SC; 6 animals/diet), intravenous (IV; 6 animals/diet) and control (CT; 3 animals/
diet). Subcutaneous (SC) mice were subcutaneously inoculated with 1  106 B16-F10 melanoma
cells suspended in 0.1 mL phosphate buffered saline (PBS) into the dorsal skinfold and monitored
for the development of palpable tumours for 14 days. Afterwards, mice were sacrificed, the tumours
were excised and paraffin-embedded for histological analysis. Tumour dimensions were determined
along the major (length) and minor axis (width) with an digital caliper and tumour volume was cal-
culated according to the formula: 0:52 length (width)2. IV animals were intravenously injected
in the tail vain with 2  105 B16-F10 cells in 0.25 mL 0.9% saline. Three weeks later, mice were
sacrificed, the lungs were excised and paraffin-embedded for histological analysis. Control animals
were not injected with B16-F10 cells and weremelanoma free. Blood was collected from all animals,
spun at 14,000 rpm for 5 mins at 4ºC and the supernatant stored for molecular analyses. All proce-
dures were conducted by accredited personnel, in accordancewith the EuropeanCommunity policy
for Experimental Animal Studies [European Community law dated fromNovember 24th 1986 (86/
609/CEE) with addendum from June 18th 2007 (2007/526/CE)] and under the supervision of the
animal facility veterinary.
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4.2.4 Histologic Analysis
Tissues were fixed in 10% neutral buffered formalin, dehydrated and embedded in paraffin. Histo-
logical 4 μm thickness sections were stained with hematoxylin and eosin (H&E) for histopathologi-
cal analyses.
4.2.5 CD31 Immunohistochemistry
Sections of paraffin-embedded tumour tissues were deparaffinized and rehydrated. Thermal anti-
gen retrieval was done in 10 mM sodium citrate (Merck) buffer (pH 6) at 98ºC for 20 min. After-
wards, slides were incubated in 3%H2O2, and blocked with a solution of 2% bovine serum albumin
(Sigma) and 10% normal swine serum in PBS. Immunohistochemistry was conducted with the rab-
bit anti-CD31 primary antibody (1:100; Abcam), biotinylated goat anti-rabbit secondary antibody
(1:200; Santa Cruz Biotechnology), streptavidin-horseradish peroxidase (Vectastain Elite), 1,3-di-
aminobenzidine tetrahydrochloride (Abcam) and counterstained with hematoxylin. Microvessel
area was determined by measuring CD31 endothelial vessels area with the help of ImageJ software
(NIH) and normalizing by dividing over the total tissue area.
4.2.6 Periodic Acid–Schiff Reaction
The periodic acid-Schiff (PAS) reaction in tissue sections was conducted as previously described.
Briefly, slides were deparaffinized, rehydrated and immersed for 10minutes in a 10% (w/v) periodic
acid solution (Merck) followed by 20 minutes incubation with Schiff reagent (Panreac) in a dark
chamber. Afterwards, slides were counterstained with hematoxylin and mounted for microscopic
observation.
4.2.7 Melanin Staining andQuantification
Melanin staining was conducted according to the Fontana-Masson method. Briefly, slides were
deparaffinized, rehydrated and incubatedwith the ammoniacal silver solution at 56ºC for 40minutes.
The precipitate was fixed with a 5% (w/v) sodium thiosulfate solution and the cells counter-stained
withnuclear fast red for 5minutes. Melanin-positive areaswerephotographedat 200magnification
and staining intensities were quantified with ImageJ software (NIH).
4.2.8 Metastasis Assessment
Three random H&E-stained paraffin-embedded lung sections from each IV animal were micro-
scopically inspected for metastasis presence. The number of metastasis found was reconfirmed for
the presence of melanin deposits in Fontana-Masson stained slides.
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4.2.9 Microvessel and VasculogenicMimicry Density Determination
Tumour allograft microvessel and VM density were evaluated under a light microscope at 400
magnification. In consecutive CD31 immunohistochemistry-stained and PAS-stained tumour sec-
tions, thenumberof endothelial vessels (CD31-positive andPAS-positive) andVMchannels (CD31-
negative and PAS-positive) were counted throughout the whole section. Three CD31/PAS tissue
sections for eachSC tumourwere analyzed andnormalized to the total tissue area. Anegative control
was included. Both positive-stained endothelial cells or clusters that were separated from adjacent
vessels were considered an individual vessel. VM channels were double checked for the presence of
lumen erythrocytes in H&E stained sections.
4.2.10 Adipokine and Angiogenesis Antibody Arrays
Mouse adipokine and angiogenesis antibody arrays (# ARY-013 and ARY-015, repectively; R&D
systems)were performed using 500 μL of pooled serum fromboth SD andHFDcontrol animals and
following themanufacturer’s protocol. The relative pixel density of each spot was calculatedwith the
microarray profiler plugin of ImageJ software (NIH).
4.2.11 Statistical Analysis
When analysing the influence of the diet (SD or HFD) in only one parameter an unpaired two-
tailedMann-Whitney nonparametric testwas used. Statistical dependence of two variableswas com-
puted by Spearman’s rank correlation. To test for differences in animal weight gain and tumour vol-
ume progression among the groups repeated measures two-way ANOVA with the diet as the cate-
gorical independent variable and time as the repeated measure factor was executed. If a significant
interaction occurred, Sidak post-hoc multiple comparisons test was subsequently performed. All
data are presented as mean ± standard error of themean (SEM). Differences with a P value less than
0.05 were considered statistically significant. All analyses were carried out in GraphPad Prism 7.0
Software (GraphPad Software Inc.).
4.3 Results
4.3.1 High-FatDietCausesSignificantWeightGainandIncreasesSerum
Levels of Growth and Angiogenic Factors in C57Bl/6J Mice
High-fat feeding significantly increased body weight gain in C57Bl/6J mice to a great extent than
standard-fed animals. Mice weight began to increase as soon as 7 weeks after HFD feeding and the
weight differences between SD and HFD groups became more prominent. At the beginning of the
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Figure4.1:Weight gain and serumprofiles ofHFDandSDchallengedC57Bl/6Jmice. A)HFDfeeding signif-
icantly increased the weight of HFD animals as compared to SD-fed animals. B)Leptin and AgRP adipokines
are elevated in HFD animals, whereas adiponectin and resistin levels are not significantly altered. C) HGF
and FGFs, particularly FGF-21, were present at considerably higher concentrations in HFD animals serum.
D) Increased relative levels of IL-10, IL-11, PAI-1 and MCP-1 were found within serum of HFD mice. E)
Obese animals exhibit greater levels of angiogenin, VEGF-A, and VEGF-B and other angiogenic factors. Bars
represent mean values (±SEM) (P < 0:05HFD vs SD)
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tumour challenge, 26 weeks after diet introduction, SDmice average weight was 31:07 g as compared
to 40:53 g in HFD animals (Fig. 4.1a).
The relative abundance of numerous adipokines and angiogenic factors in pooled serum collected
from both SD and HFD-fed CT animals was accessed by antibody microarrays (see Supplemen-
tal data). Adiposity gain was accompanied by changes in the serum levels of several circulating
molecules in C57Bl/6J mice. Serum profiles of growth-factors, adipokines, cytokines, and angio-
genesis-related molecules were different between animals on SD and HFD regimens. HFD mice
showed a noticeable increase (2.0-fold) in leptin as well as Agouti-related protein (AgRP) levels,
but no significant decrease in serum adiponectin or resistin levels (Fig. 4.1b). The levels of several
growth factors were also analyzed. HFD animals had higher circulating levels of fibroblast growth
factor (FGF)s, in particular FGF-21 (5.0-fold), hepatocyte growth factor (HGF) and insulin-like
growth factor-binding protein (IGFBP)-1, whereas insulin-like growth factor (IGF)-I levels were
significantly decreased (Fig. 4.1c). The levels of the interleukin (IL)-10, IL-11 were also signifi-
cantly higher within HFD animals and accompanied with no significant alteration in the concentra-
tion of IL-6 (Fig. 4.1d). Angiogenesis stimulators A disintegrin and metalloproteinase with throm-
bospondin motifs (ADAMTS)-1, amphiregulin, angiogenin, and vascular endothelial growth factor
(VEGF)-A and VEGF-B were significantly more abundant in overweight animals, as well as anti-an-
giogenic tissue inhibitor ofmetalloproteinases (TIMP)-4was also significantly elevated. Conversely,
proliferin was significantly decreased in overweight animals as compared to lean mice (Fig. 4.1e).
4.3.2 Fat-Rich Diet Promotes Melanoma Progression and Vascular-
ization
Our previous studies showed that adipocyte secretome was particularly rich in pro-angiogenic
factors and these adipose-derived factors favoured the in vitro development of VM structures as
well. (207) Therefore, we next examined the effects of the HFD in vascular and VMmicrocirculation
of C57Bl/6 SC-implanted melanomas. Upon inoculation, B16-F10 tumours became palpable from
day 8 and 9 onwards for the HFD and SD groups, respectively. SC tumours from HFD-fed mice
displayed a marked expansion, with an average volume approximately twice the size of melanomas
in SD animals (2.7 cm3 and 1.3cm3, respectively; Fig. 4.2a). Moreover, tumour volume posi-
tively correlated with weight gain (r = 0:83; P = 0:0049; Fig. 4.2b). Analysis of Fontana-Masson
stained tumour tissue sections (Fig. 4.2d) indicated that themelanin pigmentationwas not different
between tumours fromHFD and SD diet regimens (Fig. 4.2c).
VM tubules characteristically have tumour cells, but not endothelial cells, covering the lumen
of channel-like structures. (225) To distinguish VM from endothelial-lined vessels, we performed im-
munostaining for the CD31 endothelial marker and PAS reaction for basal membrane in consecu-
tive tumour sections. While endothelium vessels are lined by spindle-shape endothelial cells and
surrounded by basement membrane, thus staining positive for both CD31 and PAS, VM tumour
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Figure 4.2: A) C57Bl/6J tumours from HFD and SD-fed animals became measurable from day 9 and 10
onwards, respectively. Tumours fromHFDmice progressed more rapidly and had significant higher volumes
than SD-fed animals. B)Melanoma volumewas significantly correlatedwithweight gain. C)Tumourmelanin
content from both SD and HFD groups. D) Representative images of Fontana-Masson stained melanoma
sections are shown (100). Bars represent mean values ±SEM (P < 0:05HFD vs SD; n=6)
cell-lined blood channels are CD31-negative and only the basement membrane is positive for PAS
staining (Fig. 4.3d).
Enhanced tumour growth, in HFD-fed animals, was accompanied by a significantly higher mi-
crovessel density in SC tumours (Fig. 4.3a). Not only the number of endothelium-lines vessels was
elevated in HFD tumour-bearing animals, but also a parallel increase in the microvessel total occu-
pied area was observed (Fig. 4.3b). Moreover, PAS-positive VM channels were detected in both
HFD and SD melanomas. However, in comparison to SD-fed animals, only a small increase in the
number of cell-lined vessel-like structures was observed in HFD-treated mice (Fig. 4.3c).
4.3.3 High-Fat Diet Decreases B16-F10 LungMetastasis
Malignant melanocytes lung colonization potential is associated with tumour microvascular den-
sity. (99) To evaluate the in vivo effects ofHFD and adipose-derived circulating factors in the ability of
melanoma cells tometastasise, we intravenously injectedB16-F10 cells into the tail vein ofC57Bl/6J
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utive CD31 immunohistochemistry, PAS and H&E stained tumour sections. D) Representative images
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channels (CD31-negative and PAS-positive). Endothelial cell are stained by CD31 immunohistochemistry
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mice. Three weeks upon inoculation, lungs from bothCT and IVmice were collected and processed
for furthermicroscopic observation. Histopathologic analysis ofH&E lung sections revealed amore
inflamed environment, with increased septal thickening, intra-alveolar hemorrhages, peribronchial
lymphocytic infiltrate accumulation, abnormal deposition of hemosiderin and a notorious decrease
in total alveolar volume in the lungs of both CT and IV diet-induced obese animals. No significant
parenchymal alterations were found in the lungs of SD animals (Fig. 4.4d).
In B16-F10 IV-inoculatedmice, 5 out of 6 SD animals (83%) developed lungmetastases by the
end of the metastasis challenge, however in only 2 out of 6 HFD-fed animals (33%) lung metas-
tases were present (Fig. 4.4a). In fact, not only less HFD animals exhibited metastases, but they
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Figure 4.4: Intravenous injection of B16-F10 cells more readily formed lung metastases in lean animals (A)
and thenumberof developedmetastases correlates inverselywith the animalweight (B).Thenumberofmetas-
tases found is significantly higher in SD vsHFD groups (C), however no differences were found in the mean
metastases area (E).D) Representative images of H&E and Fontana-Masson stains in lung sections from SD
and HFD animal (200). Black arrows represent histological changes of lungs (peribronchial inflammatory
cells and hemosiderin deposition). F)Melanin pigmentation in lung metastases was evaluated by Fontana-
Masson stain. Bars are the means values ±SEM (P < 0:05HFD vs SD; n=6)
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also had significantly fewer metastases per lung than their leaner counterparts (6.7 and 1.7 respec-
tively; Fig. 4.4c). Interestingly, the number of metastases found inversely correlates with the weight
of the animal (r =  0:61; P = 0:038), in a diet-independent manner (Fig. 4.4b). The melanoma
metastases present in HFD animals were located in more peripheral regions of the lung and in the
pleural space, while in SD animals most metastases were perivascular. Moreover, one subcutaneous
metastasis was found in one of theHFDanimals along the necropsy (data not shown). Fontana-Mas-
son stain (Fig. 4.4d) revealed a higher melanin content in lung metastases from overweight animals
(Fig. 4.4f). The average area of the metastases was not significantly different among HFD and SD
animals (Fig. 4.4e).
4.4 Discussion
Vascularization plays a central role in tumour development and progression. (177) The awareness
that different stages of melanoma growth are associated with distinct tumour microcirculation pat-
terns (209) led us to investigate the influence of high-fat feeding in melanoma VM and angiogenesis.
Melanoma angiogenic development of endothelium-lined networks is mediated by a complex
multistep process comprising a series ofmolecularmediators that lead to tumour neovascularization.
Among these are VEGF, FGF-2, epidermal growth factor (EGF) and IL-8 as well platelet-derived
growth factor (PDGF). (83,84) In the present study, plasma concentration of VEGF-A, -B and FGF-2
was significantly increased in non-tumour-bearingHFD-fedmice compared to those fed the SDdiet.
Moreover, high-fat feeding enhanced the circulating levels of ADAMTS-1, amphiregulin and angio-
genin. Besides their angiogenesis-stimulating potential, these factors are known to be involved in
several aspects of tumourigenesis, including growth-promoting signals, tissue invasion and metasta-
sis, and resistance to apoptosis. (226–228)Genetic ablation of ADAMTS-1 inC57Bl/6mice resulted in
a drastic decrease of B16 tumour growth andmetastasis via an anti-tumourigenicmicroenvironment-
modulation effect. (229) ADAMTS-1 does not seem essential for melanoma growth, but contributes
to the acquisition of an endothelial-like phenotype by tumour cells and might be eliciting endothe-
lialmimicry byB16-F10 tumour cells. (230) Furthermore, FGF-2 confersVMfeatures and increases in
vivometastasising of melanoma cells. (231) In fact, induction of VM overcomes VEGF-A angiogenic
signaling conferringmelanomas adaptive resistance to anti-angiogenic therapies, (232) rendering VM
one of the major aggressive features of human metastatic melanoma.
In addition to angiogenic endothelium-dependent vessels, VM is another characteristic microcir-
culation pattern in melanomas. (25) In both overweight and lean tumour-bearing mice, we detected
CD31-negative PAS-positive tumour cell-lined blood vessels. However, high-fat feeding had no sig-
nificant net effect in the number of VMchannels formed. In fact, vasculogenicmimicry and endothe-
lium-lined vessel densities vary along melanoma growth. In early stages of tumour growth, vasculo-
genic mimicry predominates but, as the malignant mass expands the number of true endothelium-
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lined vessels increases and vascular microcirculation predominates. (209) Accordingly, HFD tumour-
bearing mice had a more pronounced tumour expansion, with increased microvessel density and
caliber, still a non statistically significant increase in tumour cell-line VM channels was observed.
IGF-I signaling axis has been proposed as amolecular link between obesity and the increasedmel-
anoma progression. (80) Our results disclosed significantly decreased circulating levels of IGF-I, with
a parallel elevation of free IGFBP-1 in these animals. Antagonistically, in general IGFBP-1 binds to
IGF-I, counterbalancing its effects, andmost likely contributing to the decreased free IGF-I levels ob-
served inHFD-fed animals serum. HFDanimals also exhibited large amounts of circulating FGF-21.
FGF-21 is associated with multiple benefits on obesity-related complications. (233) However, serum
FGF-21 is elevated in obese individuals and appears to be a superior predictor to other adipokines of
metabolic complications. (234) Inmelanomas, FGF-21 also increases cell proliferation in vitro accom-
panied by an increased tumourigenesis and invasive potential in vivo. (178) FGF-21 inhibits hepatic
IGF-I production (233) and may also contribute for the down-regulation of plasma IGF-I observed.
HFD-feeding increased the serum levels of IL-10, IL-11, plasminogen activator inhibitor (PAI)-1
and monocyte chemotactic protein (MCP)-1. Emerging roles for IL-11, PAI-1 and MCP-1 signal-
ing in cancer development and metastasis, that correlates with poor disease prognosis, have been
unveiled. (235–237)However, IL-10 inhibits the production of a wide range of cytokines in various cell
types, suppressing both tumour growth andmetastasis ofmelanoma cells, with a potential inhibition
of angiogenesis and tumour-associated inflammation. (238,239)
Development of distant metastases is an early event in melanoma metastatic dissemination from
the primary lesion, even from very small tumour masses. (240) As small malignant melanomas may
have already acquired vascular blood supply, it is likely that cancer cells have spread throughout
the body long before the primary melanoma is diagnosed. Our data corroborates HFD-induced
increase of tumour vascularization in melanoma xenografts. (145) In fact, primary tumour microvas-
cular density is associated withmelanoma cells lung colonization potential. (99) However, our results
disclosed an antagonistic outcome in HFD-modulated melanomametastasis. Despite the increased
microvascular density in tumours from HFD-fed SC animals and the increased circulating serum
levels of angiogenic factors present, the number ofHFD IV animals with lung-colonizingmetastases
was significantly lower than SD animals, with a concomitant decrease in the average number of lung
metastases found.
Previous studies report that fat-richdiets increasemetastasis in several other rodent cancermodels
via angiogenesis-stimulation mechanisms and factors. (235,236,241,242) However, recently it has been
shown that oxidative stress inhibits distant metastasis by human melanoma cells without signifi-
cantly interfering with the growth of subcutaneous tumours. (243) In fact, visceral adiposity is char-
acterized by a systemic increase in oxidative burden, in part through inflammation but also by in-
creased generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS). (56,70)
Furthermore, increased ROS production and oxidative stress precedes the onset of HFD-induced
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weight gain and is an initial key event triggering HFD-induced metabolic complications in C57Bl/
6J mice. (244,245) This suggests that the systemic circulation of obese animals might become more
hostile to circulating melanoma cells, than the subcutaneous environment. In fact, we have found
a cutaneous metastasis in an IV overweight animal. Obesity-associated systemic alterations might
also be decreasing the lung-specific tropismof B16-F10 cells, deviating circulatingmelanoma cells to
other organ targets. Additionally, excessive oxidative stress can impair the formation of a favourable
pre-metastatic microenvironment at distant sites, where circulating metastatic cells may engraft and
colonise, limiting the extent of successful metastasising. Nevertheless, histopathologic analysis of
lung sections from HFD melanoma-free animals revealed alterations in lung parenchyma, with in-
creased accumulation of lymphocytic infiltrate. Both systemic and local inflammation promotes
lung metastasis, so we do not conceive these alterations as a plausible mechanism bestowing the
observed B16-F10 hindered metastasising capacity. (246,247)
Melanocytes are cells specialized in melanin pigment production. Although the main function
of melanin is to protect against active oxygen species and UV-induced damage, melanoma aberrant
melanossomes have been found as an aditional source of ROS. (21) Thus, melanin pigment plays a
double role in the etiology of melanoma acting as a two-edged sword: enhancing melanocytes scav-
enger mechanism against UV and oxidative damages, but simultaneously melanossomes accelerate
melanoma progression and resistance to the effects of ROS-generating treatment therapies. (21,22,157)
Although no significant alteration in SC tumours pigmentation was observed, lung metastasis from
HFD-fed IV animals exhibited higher melanin pigment deposition. In fact, melanogenesis affects
melanoma overall and disease-free survival. Hyperpigmentedmelanomas are associated with signif-
icantly shorter disease-free survival (248) and the melanin content in melanoma metastases is a pre-
dictor of poor radiotherapy outcome, (23) renderingmelanomas ionizing radiation resistant. Accord-
ingly, themore hostile systemic circulation of obese animalsmight be exerting a selective pressure on
circulating tumour cells, allowing only more resistant and aggressive melanoma cells to successfully
metastasise, thus enhancing metastasis aggressiveness and treatment resistance.
In summary, our findings disclose a puzzling set of information. Diet-induced obesity enhanced
subcutaneous tumour growth with a concomitant increase in vascularization, raising the chances of
melanoma cells detaching from the primary tumour, enter the circulation and successfully metasta-
sise. However, obesity-associated changes in redox homeostasis might render the vascular system an
inhospitable environment for circulatingmelanoma cells, decreasing their metastatic potential, thus
preventing secondary tumour growth. Nevertheless, this pro-oxidant environment might select a
more resistant subset of circulating tumour cells rendering the metastasis formed more aggressive.
Although further in vivo studies are of paramount importance to identify the molecular pathways
involved, the current study already highlights some possible key molecular mediators.
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4.6 Supplemental Data
Table 4.s1: Serum Profile byMicroarray
Factor SD ±SEM HFD± SEM Ratio
ADAMTS1 0,0391 ±0,0023 0,0792 ±0,0056 2,02
Adiponectin 0,2296 ±0,0063 0,2511 ±0,0013 1,09
AgRP 0,0236 ±0,0002 0,0496 ±0,0023 2,10
Amphiregulin 0,0413 ±0,0041 0,0654 ±0,0118 1,58
Angiogenin 0,5347 ±0,0155 0,8491 ±0,0132 1,59
Angiopoietin-1 0,5186 ±0,014 0,5293 ±0,012 1,02
Angiopoietin-3 0,0621 ±0,0027 0,0657 ±0,0055 1,06
ANGPT-L3 0,5462 ±0,0005 0,4455 ±0,003 0,82
Coagulation Factor III 0,3202 ±0,0236 0,3514 ±0,0031 1,10
C-Reactive Protein 0,3656 ±0,0012 0,3258 ±0,004 0,89
CXCL16 1,5995 ±0,0237 1,4758 ±0,0081 0,92
Cyr61 0,3549 ±0,0064 0,4386 ±0,0079 1,24
DLL4 0,1043 ±0,0012 0,1025 ±0,0044 0,98
DPPIV 0,9356 ±0,0141 0,8138 ±0,0017 0,87
EGF 0,0349 ±0,0036 0,0281 ±0,0004 0,80
Endocan 0,8068 ±0,0083 0,8747 ±0,0097 1,08
Endoglin 0,5336 ±0,0114 0,4645 ±0,0154 0,87
Endostatin/Collagen XVIII 1,2249 ±0,0262 1,1173 ±0,0124 0,91
Endothelin-1 0,1011 ±0,0036 0,1309 ±0,0104 1,29
Fetuin A 0,2489 ±0,0025 0,197 ±0,0047 0,79
FGF-1 0,0574 ±0,0006 0,1276 ±0,0017 2,22
FGF-2 0,0457 ±0,0019 0,0865 ±0,0016 1,89
FGF-21 0,0874 ±0,0027 0,4135 ±0,0027 4,73
Fractalkine 0,3276 ±0,0027 0,2694 ±0,0069 0,82
GM-CSF 0,0574 ±0,0009 0,0458 ±0,0014 0,80
HB-EGF 0,0813 ±0,0018 0,0988 ±0,0002 1,22
HGF 0,0189 ±0,0012 0,0328 ±0,0012 1,73
ICAM-1 0,5782 ±0,0021 0,4475 ±0,0003 0,77
IGFBP-1 0,6367 ±0,002 0,9494 ±0,0007 1,49
IGFBP-2 2,0987 ±0,0254 2,0658 ±0,0216 0,98
IGFBP-3 2,7338 ±0,0293 2,6859 ±0,0149 0,98
Continued on next page
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Table 4.s1: Serum Profile byMicroarray
Factor SD ±SEM HFD± SEM Ratio
Continued from the previous page
IGFBP-5 0,9717 ±0,0094 0,8585 ±0,0171 0,88
IGFBP-6 1,2697 ±0,0011 1,0879 ±0,0135 0,86
IGF-I 0,6118 ±0,0186 0,2992 ±0,0142 0,49
IGF-II 0,0548 ±0,0031 0,0587 ±0,0119 1,07
IL-1α 0,0943 ±0,0074 0,1005 ±0,0036 1,07
IL-1ß 0,0286 ±0,0002 0,0353 ±0,0028 1,24
IL-6 0,0336 ±0,0001 0,0349 ±0,0016 1,04
IL-10 0,0168 ±0,0002 0,0217 ±0,0001 1,30
IL-11 0,021 ±0,0029 0,0372 ±0,0026 1,77
IP-10 0,0876 ±0,0039 0,0586 ±0,0037 0,67
KC 0,1439 ±0,0068 0,1427 ±0,0126 0,99
KGF 0,043 ±0,0075 0,0389 ±0,0029 0,90
Leptin 0,7482 ±0,0117 1,5518 ±0,0005 2,07
LIF 0,0556 ±0,0029 0,0432 ±0,0067 0,78
Lipocalin-2 1,3558 ±0,0062 0,9176 ±0,0174 0,68
MCP-1 0,1451 ±0,0097 0,2179 ±0,0075 1,50
M-CSF 0,5359 ±0,0016 0,5743 ±0,0057 1,07
MIP-1α 0,2071 ±0,0002 0,1769 ±0,0005 0,85
MMP-3 (pro and mature form) 3,7499 ±0,0817 3,6736 ±0,036 0,98
MMP-8 (pro form) 1,4113 ±0,046 1,2953 ±0,037 0,92
MMP-9 (pro and active form) 2,2327 ±0,0424 1,969 ±0,0204 0,88
NOV 2,7234 ±0,0697 2,4931 ±0,0528 0,92
Oncostatin M 0,0489 ±0,0051 0,0273 ±0,0003 0,56
Osteopontin 1,5382 ±0,0043 1,1231 ±0,0004 0,73
PD-ECGF 0,0629 ±0,0067 0,0496 ±0,0071 0,79
PDGF-AA 0,1612 ±0,004 0,1426 ±0,0117 0,88
PDGF-AB/PDGF-BB 1,0405 ±0,0288 0,914 ±0,0309 0,88
Pentraxin 2 0,496 ±0,0011 0,356 ±0,0057 0,72
Pentraxin 3 0,4541 ±0,0014 0,3724 ±0,0052 0,82
Pentraxin-3 1,2756 ±0,0067 1,0924 ±0,0132 0,86
Platelet Factor 4 0,7515 ±0,0069 0,6848 ±0,0102 0,91
PlGF-2 0,8404 ±0,0005 1,0469 ±0,0026 1,25
Continued on next page
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Table 4.s1: Serum Profile byMicroarray
Factor SD ±SEM HFD± SEM Ratio
Continued from the previous page
Pref-1 0,1727 ±0,0092 0,1148 ±0,0024 0,66
Prolactin 0,8047 ±0,0414 0,7208 ±0,0249 0,90
Proliferin 0,133 ±0,0149 0,0762 ±0,0036 0,57
RAGE 0,3759 ±0,001 0,6757 ±0,0002 1,80
RANTES 0,0294 ±0,0034 0,0293 ±0,0052 1,00
RBP4 0,1829 ±0,0115 0,1665 ±0,0194 0,91
Resistin 1,4301 ±0,0311 1,4363 ±0,0413 1,00
SDF-1 0,4251 ±0,007 0,3366 ±0,0008 0,79
Serpin E1 0,8465 ±0,0028 1,2647 ±0,0187 1,49
Serpin F1 1,1474 ±0,0071 1,2118 ±0,0102 1,06
Thrombospondin-2 0,1793 ±0,0107 0,1929 ±0,0117 1,08
TIMP-1 0,5903 ±0,0115 0,5684 ±0,0172 0,96
TIMP-4 1,6214 ±0,0579 2,1735 ±0,0017 1,34
TNF-α 0,0169 ±0,0007 0,0191 ±0,002 1,13
VEGF-A 0,1287 ±0,0006 0,2093 ±0,0035 1,63
VEGF-B 0,0975 ±0,0191 0,1815 ±0,002 1,86
Values are fold-increase relative to positive internal controls. Values are averages of twomeasure-
ments.
Legend: ADAMTS1: A disintegrin and metalloproteinase with thrombospondin motifs 1;
AgRP: Agouti-related peptide; ANGPT-L3: angiopoietin-like 3; CXCL16: CXC chemokine
ligand 16; Cyr61: cysteine rich protein 61; DLL4 deltalike protein 4; DPP-IV: dipeptidyl pep-
tidase 4; EGF: epidermal growth factor; FGF: fibroblast growth factor; GM-CSF: granulocyte
macrophage colony stimulating factor; HB-EGF: heparin binding EGF-like growth factor; HGF:
hepatocyte growth factor; ICAM-1: intercellular adhesion molecule 1; IGF: insulin-like growth
factor; IGFBP: insulin-like growth factor-binding protein; IL: interleukin; IP: inducible pro-
tein; KC: mouse homolog of human GRO; LIF: leukemia inhibitory factor; MCP-1: monocyte
chemotactic protein 1;M-CSF:macrophage colony-stimulating factor;MIP:macrophage inflam-
matory protein; NOV: nephroblastoma overexpressed; Pref-1: preadipocyte factor 1; PD-ECGF
platelet derived endothelial cell growth factor; PDGF: platelet derived growth factor; PlGF-2:
placenta growth factor-2;RAGE: receptor for advanced glycation endproducts;RANTES: regu-
lated upon activation normal T cell expressed and presumably secreted; RBP4: retinol binding
protein 4; SDF-1: stromal cell-derived factor 1; TIMP-1: tissue inhibitor of metalloproteinase 1;
TNF-α: tumour necrosis factor alpha; VEGF: vascular endothelial growth factor.
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General Discussion
A dipose tissue (AT) releases multiple bioactive molecules and systemic factors, includinggrowth factors and inflammatory, angiogenic or metabolic markers. Deregulated produc-tion and/or secretion of these adipokines, an hallmark of excess adiposity and AT dysfunc-
tion, contributes to the pathogenesis of obesity and its comorbid conditions and significantly influ-
ences tumour behavior. (62,64,70,177)
Moreover, obesity provides a chronic low grade inflammatory condition, further potentiated by
the presence of adipose-released hormone cues and pro-inflammatory cytokines, which are strongly
associatedwith cancer progression and tumour-associatedmacrophage accumulation. Macrophages
release factors that paracrinallymodulate tumour plasticity and themaintenance of stromalmicroen-
vironment. (143) In contrast, our in vitro results disclosed a direct effect of adipocytes on melanoma
cells, without the influence of neither tumour-associated cell-mediated immunity nor systemic in-
flammation. Adipocyte-released factors play a role in increasing melanoma cell overall survival, by
directly increasing melanoma cell proliferation and simultaneously diminishing programmed cell
death. Exposure to ex vivoATorgan culture conditionedmedium(CM) further resulted in increased
motility, enhancing the capacity of melanocytes to migrate and spread. These findings were accom-
panied by a greater adhesion capacity, in particular to endothelial cells. Moreover, adipose CMmin-
imized melanocytes anoikis, overcoming the apoptotic response to the absence of cell–matrix inter-
actions and potentiated anchorage-independent proliferation, reinforcing the aggressive and meta-
static potential of paracrinally adipocyte-stimulated melanocytes.
Visceral adiposity accumulation is accompanied by a systemic increase in oxidative stress, in part
through low grade inflammation but also by increased generation of reactive oxygen species (ROS)
and reactive nitrogen species (RNS). (56,70) Besides their damaging effects, ROS and pro-oxidants
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are key mediators in the regulation and homeostasis of several signal transduction pathways in can-
cer cells. (150) Obesity-associated impaired antioxidant defences (55) and ROS produced from peritu-
moural adipose tissue exacerbate oxidative stress within tumour cells and might contribute to the
carcinogenic process in obese patients. Nevertheless, our in vitro studies revealed that adipocyte
CM growth promoting effects overcome the adipocyte-associated pro-oxidant environment, lessen-
ing the radiation therapy (RT)-induced damages. Cellular metabolic activity and antioxidant de-
fences of irradiated melanocytes were improved, with enhanced antioxidant capacity and decreased
oxidative stress, even with cumulative ionizing radiation doses. Activation of AKT-mediated pro-
proliferative and anti-apoptotic stimuli supplant the adipocyte-derived ROS, enhancing melanoma
cells antioxidant defences and endorsing adaptative resistance to the effects of ROS-generating treat-
ment therapies. Thus, an environment rich in adipocyte-released factors protects melanocytes from
radiation-induced oxidative stress and viability loss, circumventing the efficacy of RT treatments,
contributing to melanomas radioresistance.
To successfully metastasise malignant cells must first escape from the primary cancer, shed into
the vascular systemwhere then they are carried around the body in the circulation, triggering amech-
anism that is responsible for the majority of cancer-related deaths. (184) Tumour angiogenesis has a
pivotal role to provide enough oxygen and nutrients to sustain the exacerbated cancer growth. How-
ever, tumour neovascularization also provides malignant cells an entry point to the vasculature to
metastasise. Our in vivo results demonstrated that adiposity-enhancedmelanoma growth is followed
by a strong angiogenic response. Tumours develop more capillaries and their caliber expands, pro-
viding the growing malignant mass further access to blood flow to sustain its growth. In addition
to angiogenesis, melanoma cells are capable of shifting towards an endothelial-like phenotype. Vas-
culogenic mimicry (VM) is a characteristic microcirculation pattern in melanomas, where tumour
cell-lined vascular channels are capable of sustaining a parallel blood supply, with a viable blood flow
between VM vascular spaces and endothelium-lined vasculature, not only further nourishing the
tumour but also providing an alternative access to systemic circulation, thus enhancing metastasis-
ing likeliness. (249) Our results evidenced that upon exposure to adipocyte and AT CM melanoma
cells rearranged, on 3D in vitro cultures, into characteristic VM vessel-like structures. However, in
tumour-bearing high-fat diet (HFD) animals no significant increase in VM density was observed.
Nevertheless, in the early stages of melanoma growth VM predominates and as the tumour mass
develops these VM-channels are gradually replaced by endothelium-lined vessels. (209) In fact, HFD
animals beared significantly larger tumours but, instead of a decreased VMdensity, a non significant
increase in tumour-cell-lined vessels was observed, providing some evidence of in vivo obesity-en-
hanced VM.
The ability to enter circulation is not the only factor that limits distant metastasis. When in cir-
culation malignant cells must properly adapt to survive in a completely different environment until
they find a favourable niche where they can engraft and colonise for secondary tumour growth. Our
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in vivo lung metastasis results disclosed an intriguing set of information. Despite HFD-induced ex-
pansion of tumour vasculature, raising the chances of melanoma cells detaching from the primary
tumour and enter into circulation, lung-colonizing metastasis were significantly lower for HFD-fed
animals than standard diet (SD) animals. In fact, obesity-associated changes in circulating factors
and oxidative stress might render the vascular system an inhospitable environment for circulating
melanoma cells, decreasing their metastatic potential, thus preventing secondary tumour growth.
The decreased viability of circulating melanoma cells might be exerting a selective pressure on cir-
culating melanoma cells, allowing only more resistant and aggressive melanoma cells to successfully
metastasise, thus enhancing melanomametastasis aggressiveness and treatment resistance.
We focused on growth factors, angiogenic cytokines and adipokines in our search formechanisms
of hight-fat dietary-enhanced melanoma progression. Molecular characterization of adipose-associ-
ated serum factors, as well as in vitro adipocytes CM, led us to highlight possible mechanisms by
which adipose tissue promotes melanoma progression. Increasing levels of fibroblast growth factor
(FGF)-2, FGF-21, hepatocyte growth factor (HGF), interleukin (IL)-10 and vascular endothelial
growth factor (VEGF)were detected in both adipocytes secretome and obese animals serum. These
.
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Figure 5.1: Possible newmolecular players and mechanisms linking obesity and melanoma.
Legend: FGF: fibroblast growth factor; HGF: hepatocyte growth factor; IL: interleukin; VEGF: vascular endothelial
growth factor.
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molecular messengers allied to enhanced angiogenesis and VM have putative roles in melanoma eti-
ology, prognosis and treatment resistance, representing novel prospective therapeutical targets in
the obesity-melanoma rationale. Moreover, melanogenesis and melanin pigment play a role in mel-
anoma etiology. Despite the relationship between melanin content and metastatic phenotype of
melanoma still remains controversial, hyperpigmented melanomas are associated with significantly
shorter disease-free survival (248) and the melanin content in melanoma metastases is a predictor of
poor radiotherapy outcome, (23) rendering melanomas ionizing radiation resistant. Accordingly, the
higher pigmented metastases found in the lungs of overweight animals might be composed of more
resistant and aggressive melanoma cells, thus enhancing metastasis aggressiveness and treatment re-
sistance. Figure 5.1 summarizes the main mechanistic links and molecular players tying obesity and
melanoma that were disclosed by our findings. However, these mechanisms are not mutually ex-
clusive, nor reject the involvement of other inherent biological systems in this malignant process.
Most likely, the relationship between obesity-associated melanoma development is multifactorial
and surely complex multi-systemmechanisms synergetically co-exist.
According to the International Agency for Research on Cancer, the strength of the evidence of
the association between body fatness and melanoma in human available studies is inadequate. (250)
It is of uttermost importance that more fundamental and clinical studies are performed to acquire
a more clear understanding of the obesity-melanoma relation. Nevertheless, our results add up to
accumulating contemporary evidence and epidemiologic data and further strengthen the association
between obesity and malignant melanoma progression. (63–65,74,145,160,207) Moreover, high adiposity
is associated not only with cancer prevalence, but obesity and its co-morbidities also worsen disease
progression, with a negative impact in prognosis and overall survival from the most common forms
of cancer in obese patients. (61,62)
Clinical management and control of obesity, either by caloric restriction or with antiobesity phar-
macologic treatments, appears an attractive target to arrest obesity-promoted tumour progression
and improve the prognosis and survival of obese cancer patients. Our results disclosed a duality in
the contribution of adiposity to melanoma progression and metastasis. Adipose-derived factors act
as a two-edged sword: promoting subcutaneous primary tumour progression and vascularization,
but simultaneously lessening distant metastases formation and secondary cancer growth. Further-
more, weight loss is a common feature among cancer patients and is often one of the first noticeable
symptoms of the disease. Weight loss correlates with poorer median survival, emphasizing the prog-
nostic importance of weight loss along cancer treatment. In fact, cancer patients with weight loss
share poor prognosis, regardless of their pre-diagnostic bodyweight. (251) In the absence of solid clin-
ical data, both normoponderal and overweight patients should be advised to maintain their weight
and avoid abrupt weight variations along cancer treatment. Our findings also reinforce the need
for the clinician to take into account whether the patient is normoponderal or overweight in treat-
ment planning, as adiposity-associated different mechanisms of cancer pathogenesis might lead to
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distinct outcomes. Nevertheless, enough evidence exists to endorse recommendations that both
children and adults maintain an average weight for their height and ages for multiple health benefits,
including decreasing their risk of malignant melanoma.
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